uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q22.678 | Q22 | What is Ingrezza? | Ingrezza, also known generically as Valbenazine Tosylate, was approved by the FDA in 2017 to treat movement disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ingrezza%" OR LOWER(tradeNames_string) LIKE "%ingrezza%" OR LOWER(drugSynonyms_string) LIKE "%ingrezza%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5423', 'tradeNames_string': 'Ingrezza', 'drugName': 'Valbenazine Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Synaptic vesicular amine transporter inhibitor', 'linkedDiseasesDrug_string': 'Movement Disorder (EFO_0004280)', 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.346 | Q22 | What is Lenvima? | Lenvima, also known generically as Lenvatinib Mesylate, was approved by the FDA in 2015 to treat renal cell carcinoma, thyroid carcinoma, and thyroid cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lenvima%" OR LOWER(tradeNames_string) LIKE "%lenvima%" OR LOWER(drugSynonyms_string) LIKE "%lenvima%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3026', 'tradeNames_string': 'Lenvima', 'drugName': 'Lenvatinib Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Thyroid Carcinoma (EFO_0002892), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Metastatic Melanoma (EFO_0002617), Intrahepatic Cholangiocarcinoma (EFO_1001961), Carcinoma (EFO_0000313)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6114', 'tradeNames_string': 'Kisplyx, Lenvima', 'drugName': 'Lenvatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Adenoid Cystic Carcinoma (EFO_0000231), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Intrahepatic Cholangiocarcinoma (EFO_1001961), Endometrial Cancer (MONDO_0011962), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Neuroendocrine Carcinoma (MONDO_0002120), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Chronic Hepatitis B Virus Infection (EFO_0004239), Colorectal Neoplasm (EFO_0004142), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Gastric Carcinoma (EFO_0000178), Central Nervous System Neoplasm (EFO_1000158), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Glioma (EFO_0005543), Carcinoma (EFO_0000313), Biliary Tract Neoplasm (EFO_0003891), Endometrial Neoplasm (EFO_0004230), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Leptomeningeal Metastasis (EFO_1001012), Chondrosarcoma (EFO_0000333), Rectum Cancer (EFO_1000657), Merkel Cell Skin Cancer (EFO_1001471), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Esophageal Squamous Cell Carcinoma (EFO_0005922), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Nasopharyngeal Neoplasm (EFO_0004252), Classic Hodgkin Lymphoma (MONDO_0009348), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086), Uterine Carcinosarcoma (EFO_1000613), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.3 | Q22 | What is Yonsa? | Yonsa, also known generically as Abiraterone Acetate, was approved by the FDA in 2011 to treat metastatic prostate cancer, cancer, neoplasm, prostate adenocarcinoma, prostate carcinoma, and prostate cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%yonsa%" OR LOWER(tradeNames_string) LIKE "%yonsa%" OR LOWER(drugSynonyms_string) LIKE "%yonsa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2354', 'tradeNames_string': 'Yonsa, Zytiga', 'drugName': 'Abiraterone Acetate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cytochrome P450 17A1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Congenital Adrenal Hyperplasia (MONDO_0018479), Metastatic Prostate Cancer (EFO_0000196), Renal Insufficiency (HP_0000083), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728)', 'newLinkedTargets_string': 'CYP17A1 (ENSG00000148795)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.231 | Q22 | What is Steglatro? | Steglatro, also known generically as Ertugliflozin, was approved by the FDA in 2017 to treat diabetes mellitus and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%steglatro%" OR LOWER(tradeNames_string) LIKE "%steglatro%" OR LOWER(drugSynonyms_string) LIKE "%steglatro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3216', 'tradeNames_string': 'Steglatro', 'drugName': 'Ertugliflozin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Sodium/glucose cotransporter 2 inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Heart Failure (EFO_0003144)', 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.84 | Q22 | What is Bevyxxa? | Bevyxxa, also known generically as Betrixaban, was approved by the FDA in 2017 to treat Recurrent thrombophlebitis and venous thromboembolism. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bevyxxa%" OR LOWER(tradeNames_string) LIKE "%bevyxxa%" OR LOWER(drugSynonyms_string) LIKE "%bevyxxa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5169', 'tradeNames_string': 'Bevyxxa', 'drugName': 'Betrixaban', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Coagulation factor X inhibitor', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Atrial Flutter (EFO_0003911), Hemorrhage (MP_0001914), Liver Disease (EFO_0001421), Kidney Disease (EFO_0003086), Venous Thromboembolism (EFO_0004286), Thromboembolism (HP_0001907), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'F10 (ENSG00000126218)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.480 | Q22 | What is Isturisa? | Isturisa, also known generically as Osilodrostat Phosphate, was approved by the FDA in 2020 to treat pituitary-dependent Cushing's disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isturisa%" OR LOWER(tradeNames_string) LIKE "%isturisa%" OR LOWER(drugSynonyms_string) LIKE "%isturisa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5216', 'tradeNames_string': 'Isturisa', 'drugName': 'Osilodrostat Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cytochrome P450 11B1 inhibitor', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110)", 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.701 | Q22 | What is Prialt? | Prialt, also known generically as Ziconotide, was approved by the FDA in 2004 to treat Fever and pain. It is a protein therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prialt%" OR LOWER(tradeNames_string) LIKE "%prialt%" OR LOWER(drugSynonyms_string) LIKE "%prialt%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2513', 'tradeNames_string': 'Prialt', 'drugName': 'Ziconotide', 'drugMolecularType': 'Protein', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated N-type calcium channel alpha-1B subunit blocker', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Fever (HP_0001945)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4779', 'tradeNames_string': 'Prialt', 'drugName': 'Ziconotide Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated N-type calcium channel alpha-1B subunit blocker', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Fever (HP_0001945)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.672 | Q22 | What is Triptodur Kit? | Triptodur Kit, also known generically as Triptorelin Pamoate, was approved by the FDA in 2000 to treat prostate adenocarcinoma, prostate carcinoma, Central precocious puberty, and precocious puberty. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%triptodur kit%" OR LOWER(tradeNames_string) LIKE "%triptodur kit%" OR LOWER(drugSynonyms_string) LIKE "%triptodur kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4710', 'tradeNames_string': 'Trelstar, Triptodur kit', 'drugName': 'Triptorelin Pamoate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Central Precocious Puberty (EFO_0009029), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Endometriosis (EFO_0001065), Precocious Puberty (MONDO_0000088), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.611 | Q22 | What is Nucynta? | Nucynta, also known generically as Tapentadol Hydrochloride, was approved by the FDA in 2008 to treat Chronic pain, pain, and neuropathic pain. It is a small molecule therapy that acts as a(n) agonist and inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nucynta%" OR LOWER(tradeNames_string) LIKE "%nucynta%" OR LOWER(drugSynonyms_string) LIKE "%nucynta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6372', 'tradeNames_string': 'Nucynta, Nucynta er, Palexia', 'drugName': 'Tapentadol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Neuropathic Pain (EFO_0005762)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6373', 'tradeNames_string': 'Nucynta, Nucynta er, Palexia', 'drugName': 'Tapentadol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Neuropathic Pain (EFO_0005762)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.123 | Q22 | What is Carnexiv? | Carnexiv, also known generically as Carbamazepine, was approved by the FDA in 1968 to treat Seizure, bipolar disorder, epilepsy, partial epilepsy, bipolar I disorder, and trigeminal neuralgia. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carnexiv%" OR LOWER(tradeNames_string) LIKE "%carnexiv%" OR LOWER(drugSynonyms_string) LIKE "%carnexiv%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5883', 'tradeNames_string': 'Arbil mr, Carbagen sr, Carbamazepine, Carbatrol, Carnexiv, Epimaz, Epimaz ret, Epitol, Equetro, Sirtal ret, Tegretol, Tegretol Xr, Tegretol chewtab, Tegretol prolonged release, Tegretol-xr, Teril, Teril ret, Timonil 200 ret, Timonil 400 ret', 'drugName': 'Carbamazepine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Hiv Infection (EFO_0000764), Bipolar I Disorder (EFO_0009963), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Seizure (HP_0001250), Hepatitis B Virus Infection (EFO_0004197), Dementia (HP_0000726), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985), Trigeminal Neuralgia (EFO_1001219), Photosensitive Epilepsy (MONDO_0015643)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1968, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.315 | Q22 | What is Fanapt? | Fanapt, also known generically as Iloperidone, was approved by the FDA in 2009 to treat psychosis and schizophrenia. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fanapt%" OR LOWER(tradeNames_string) LIKE "%fanapt%" OR LOWER(drugSynonyms_string) LIKE "%fanapt%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4312', 'tradeNames_string': 'Fanapt, Iloperidone', 'drugName': 'Iloperidone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Post-Traumatic Stress Disorder (EFO_0001358), Bipolar I Disorder (EFO_0009963), Liver Disease (EFO_0001421), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4313', 'tradeNames_string': 'Fanapt, Iloperidone', 'drugName': 'Iloperidone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Dopamine D2 receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Post-Traumatic Stress Disorder (EFO_0001358), Bipolar I Disorder (EFO_0009963), Liver Disease (EFO_0001421), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.207 | Q22 | What is Angeliq? | Angeliq, also known generically as Drospirenone, was approved by the FDA in 2001 to treat acne. It is a small molecule therapy that acts as a(n) agonist and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%angeliq%" OR LOWER(tradeNames_string) LIKE "%angeliq%" OR LOWER(drugSynonyms_string) LIKE "%angeliq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1555', 'tradeNames_string': 'Angeliq, Slynd', 'drugName': 'Drospirenone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Progesterone receptor agonist', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Binge Eating (EFO_0005924), Dysmenorrhea (HP_0100607), Acne (EFO_0003894), Premenstrual Tension (MONDO_0004169), Bulimia Nervosa (EFO_0005204), Depressive Disorder (MONDO_0002050), Hidradenitis Suppurativa (EFO_1000710)', 'newLinkedTargets_string': 'PGR (ENSG00000082175), NR3C2 (ENSG00000151623)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1556', 'tradeNames_string': 'Angeliq, Slynd', 'drugName': 'Drospirenone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Mineralocorticoid receptor antagonist', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Binge Eating (EFO_0005924), Dysmenorrhea (HP_0100607), Acne (EFO_0003894), Premenstrual Tension (MONDO_0004169), Bulimia Nervosa (EFO_0005204), Depressive Disorder (MONDO_0002050), Hidradenitis Suppurativa (EFO_1000710)', 'newLinkedTargets_string': 'PGR (ENSG00000082175), NR3C2 (ENSG00000151623)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.248 | Q22 | What is Uloric? | Uloric, also known generically as Febuxostat, was approved by the FDA in 2009 to treat gout and hyperuricemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%uloric%" OR LOWER(tradeNames_string) LIKE "%uloric%" OR LOWER(drugSynonyms_string) LIKE "%uloric%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1230', 'tradeNames_string': 'Adenuric, Uloric', 'drugName': 'Febuxostat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Xanthine dehydrogenase inhibitor', 'linkedDiseasesDrug_string': 'Gout (EFO_0004274), Hyperuricemia (EFO_0009104), Angina Pectoris (EFO_0003913), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Kidney Disease (EFO_0003086), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Tumor Lysis Syndrome (EFO_1001479), Nephrolithiasis (EFO_0004253)', 'newLinkedTargets_string': 'XDH (ENSG00000158125)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.693 | Q22 | What is Lupkynis? | Lupkynis, also known generically as Voclosporin, was approved by the FDA in 2021 to treat immune system disease and lupus nephritis. It is a protein therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lupkynis%" OR LOWER(tradeNames_string) LIKE "%lupkynis%" OR LOWER(drugSynonyms_string) LIKE "%lupkynis%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3543', 'tradeNames_string': 'Lupkynis', 'drugName': 'Voclosporin', 'drugMolecularType': 'Protein', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Anterior Uveitis (EFO_1000811), Psoriasis (EFO_0000676), Immune System Disease (EFO_0000540), Intermediate Uveitis (EFO_1000986), Kidney Disease (EFO_0003086), Panuveitis (EFO_1001082), Focal Segmental Glomerulosclerosis (EFO_0004236), Dry Eye Syndrome (EFO_1000906), Systemic Lupus Erythematosus (MONDO_0007915), Posterior Uveitis (EFO_1001119), Lupus Nephritis (EFO_0005761)', 'newLinkedTargets_string': 'PPP3CA (ENSG00000138814)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.275 | Q22 | What is Trelegy Ellipta? | Trelegy Ellipta, also known generically as Fluticasone Furoate, was approved by the FDA in 2007 to treat Nasal congestion, Airway obstruction, chronic obstructive pulmonary disease, seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trelegy ellipta%" OR LOWER(tradeNames_string) LIKE "%trelegy ellipta%" OR LOWER(drugSynonyms_string) LIKE "%trelegy ellipta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1921', 'tradeNames_string': 'Arnuity ellipta, Avamys, Flonase sensimist allergy relief, Relvar ellipta, Trelegy ellipta, Veramyst', 'drugName': 'Fluticasone Furoate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Rhinitis (EFO_0008521)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.134 | Q22 | What is Zerviate? | Zerviate, also known generically as Cetirizine Hydrochloride, was approved by the FDA in 1995 to treat seasonal allergic rhinitis, urticaria, and allergic rhinitis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zerviate%" OR LOWER(tradeNames_string) LIKE "%zerviate%" OR LOWER(drugSynonyms_string) LIKE "%zerviate%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6377', 'tradeNames_string': "Allacan, Allertek, Becoallergy, Cetec, Cetirizine hydrochloride, Cetirizine hydrochloride allergy, Cetirizine hydrochloride hives, Cetirizine hydrochloride hives relief, Cetirocol, Children's cetirizine hydrochloride allergy, Children's cetirizine hydrochloride hives relief, Children's zyrtec allergy, Children's zyrtec hives relief, Piriteze, Pollenshield, Quzyttir, Zerviate, Ziralton, Zirtek, Zynor, Zyrtec, Zyrtec allergy, Zyrtec hives relief", 'drugName': 'Cetirizine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Seasonal Allergic Rhinitis (EFO_0003956), Prostatitis (EFO_0003830), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.687 | Q22 | What is Verquvo? | Verquvo, also known generically as Vericiguat, was approved by the FDA in 2021 to treat cardiovascular disease and heart failure. It is a small molecule therapy that acts as a(n) activator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%verquvo%" OR LOWER(tradeNames_string) LIKE "%verquvo%" OR LOWER(drugSynonyms_string) LIKE "%verquvo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2605', 'tradeNames_string': 'Verquvo', 'drugName': 'Vericiguat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'activator', 'drugMechanismOfAction': 'Soluble guanylate cyclase activator', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Coronary Artery Disease (EFO_0001645), Cardiovascular Disease (EFO_0000319)', 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.61 | Q22 | What is Onureg? | Onureg, also known generically as Azacitidine, was approved by the FDA in 2004 to treat Thrombocytopenia, myelodysplastic syndrome, cancer, neoplasm, refractory anemia with excess blasts, chronic myelomonocytic leukemia, and anemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%onureg%" OR LOWER(tradeNames_string) LIKE "%onureg%" OR LOWER(drugSynonyms_string) LIKE "%onureg%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4131', 'tradeNames_string': 'Azacitidine, Onureg, Vidaza', 'drugName': 'Azacitidine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'DNA (cytosine-5)-methyltransferase 1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Acute Kidney Failure (MONDO_0002492), Non-Hodgkins Lymphoma (EFO_0005952), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Chronic Lymphocytic Leukemia (EFO_0000095), Graft Versus Host Disease (MONDO_0013730), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Central Nervous System Cancer (EFO_0000326), Metastatic Melanoma (EFO_0002617), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Malignant Colon Neoplasm (MONDO_0021063), Acute Erythroblastic Leukemia (EFO_1001257), Breast Neoplasm (EFO_0003869), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Beta-Thalassemia (Orphanet_848), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chronic Myelomonocytic Leukemia (EFO_1001779), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Pancreatic Carcinoma (EFO_0002618), Thrombocytopenia (HP_0001873), Refractory Anemia With Excess Blasts (EFO_0003811), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Anemia (MONDO_0002280), Ependymoma (EFO_1000028), Cutaneous Melanoma (EFO_0000389), Hodgkins Lymphoma (EFO_0000183), Lymphoid Leukemia (EFO_0004289), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Follicular Lymphoma (MONDO_0018906), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Squamous Cell Carcinoma (EFO_0000707), Osteosarcoma (EFO_0000637), Myeloproliferative Disorder (EFO_0004251), Leukemia (EFO_0000565), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Classic Hodgkin Lymphoma (MONDO_0009348), Neoplasm (EFO_0000616), Tuberculosis (MONDO_0018076), Beta-Thalassemia Major (MONDO_0016486), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Esophageal Cancer (MONDO_0007576), Childhood Ependymoma (MONDO_0003478)', 'newLinkedTargets_string': 'DNMT1 (ENSG00000130816), DNMT3A (ENSG00000119772)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4132', 'tradeNames_string': 'Azacitidine, Onureg, Vidaza', 'drugName': 'Azacitidine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'DNA (cytosine-5)-methyltransferase 3A inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Acute Kidney Failure (MONDO_0002492), Non-Hodgkins Lymphoma (EFO_0005952), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Chronic Lymphocytic Leukemia (EFO_0000095), Graft Versus Host Disease (MONDO_0013730), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Central Nervous System Cancer (EFO_0000326), Metastatic Melanoma (EFO_0002617), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Malignant Colon Neoplasm (MONDO_0021063), Acute Erythroblastic Leukemia (EFO_1001257), Breast Neoplasm (EFO_0003869), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Beta-Thalassemia (Orphanet_848), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chronic Myelomonocytic Leukemia (EFO_1001779), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Pancreatic Carcinoma (EFO_0002618), Thrombocytopenia (HP_0001873), Refractory Anemia With Excess Blasts (EFO_0003811), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Anemia (MONDO_0002280), Ependymoma (EFO_1000028), Cutaneous Melanoma (EFO_0000389), Hodgkins Lymphoma (EFO_0000183), Lymphoid Leukemia (EFO_0004289), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Follicular Lymphoma (MONDO_0018906), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Squamous Cell Carcinoma (EFO_0000707), Osteosarcoma (EFO_0000637), Myeloproliferative Disorder (EFO_0004251), Leukemia (EFO_0000565), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Classic Hodgkin Lymphoma (MONDO_0009348), Neoplasm (EFO_0000616), Tuberculosis (MONDO_0018076), Beta-Thalassemia Major (MONDO_0016486), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Esophageal Cancer (MONDO_0007576), Childhood Ependymoma (MONDO_0003478)', 'newLinkedTargets_string': 'DNMT1 (ENSG00000130816), DNMT3A (ENSG00000119772)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.314 | Q22 | What is Zydelig? | Zydelig, also known generically as Idelalisib, was approved by the FDA in 2014 to treat chronic lymphocytic leukemia, neoplasm of mature B-cells, cancer, neoplasm, and non-Hodgkins lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zydelig%" OR LOWER(tradeNames_string) LIKE "%zydelig%" OR LOWER(drugSynonyms_string) LIKE "%zydelig%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3742', 'tradeNames_string': 'Zydelig', 'drugName': 'Idelalisib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PI3-kinase p110-delta subunit inhibitor', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Lymphoplasmacytic Lymphoma (MONDO_0000432), Allergic Rhinitis (EFO_0005854), Mantle Cell Lymphoma (EFO_1001469), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Neoplasm Of Mature B-Cells (EFO_0000096), Waldenstrom Macroglobulinemia (EFO_0009441), Hodgkins Lymphoma (EFO_0000183), Follicular Lymphoma (MONDO_0018906), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.31 | Q22 | What is Firdapse? | Firdapse, also known generically as Amifampridine Phosphate, was approved by the FDA in 2018. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%firdapse%" OR LOWER(tradeNames_string) LIKE "%firdapse%" OR LOWER(drugSynonyms_string) LIKE "%firdapse%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3435', 'tradeNames_string': 'Firdapse', 'drugName': 'Amifampridine Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated potassium channel blocker', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Brugada Syndrome (MONDO_0015263), Spinal Muscular Atrophy (EFO_0008525), Muscle Atrophy (EFO_0009851)', 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.70 | Q22 | What is Colazal? | Colazal, also known generically as Balsalazide Disodium, was approved by the FDA in 2000 to treat ulcerative colitis. It is a small molecule therapy that acts as a(n) agonist and inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%colazal%" OR LOWER(tradeNames_string) LIKE "%colazal%" OR LOWER(drugSynonyms_string) LIKE "%colazal%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1296', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugName': 'Balsalazide Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor gamma agonist', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1297', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugName': 'Balsalazide Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1298', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugName': 'Balsalazide Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Arachidonate 5-lipoxygenase inhibitor', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.658 | Q22 | What is Ryzolt? | Ryzolt, also known generically as Tramadol Hydrochloride, was approved by the FDA in 1995 to treat Chronic pain, pain, and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ryzolt%" OR LOWER(tradeNames_string) LIKE "%ryzolt%" OR LOWER(drugSynonyms_string) LIKE "%ryzolt%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3268', 'tradeNames_string': 'Aceon, Conzip, Dromadol sr, Dromadol xl, Invodol sr, Larapam sr, Mabron, Maneo, Marol, Maxitram sr, Nobligan ret, Oldaram, Qdolo, Rybix odt, Ryzolt, Tilodol sr, Tradorec xl, Tramacet, Tramadol hydrochloride, Tramake, Tramake insts, Tramquel sr, Tramulief sr, Ultram, Ultram er, Zamadol, Zamadol 24hr, Zamadol melt, Zamadol sr, Zeridame sr, Zydol, Zydol sr, Zydol xl', 'drugName': 'Tramadol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Cancer (MONDO_0004992), Drug Dependence (EFO_0003890), Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.396 | Q22 | What is Opsumit? | Opsumit, also known generically as Macitentan, was approved by the FDA in 2010 to treat hypertension and idiopathic and/or familial pulmonary arterial hypertension. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%opsumit%" OR LOWER(tradeNames_string) LIKE "%opsumit%" OR LOWER(drugSynonyms_string) LIKE "%opsumit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5056', 'tradeNames_string': 'Opsumit', 'drugName': 'Macitentan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Endothelin receptor, ET-A/ET-B antagonist', 'linkedDiseasesDrug_string': 'Pulmonary Hypertension (MONDO_0005149), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Idiopathic And/Or Familial Pulmonary Arterial Hypertension (MONDO_0008347), Pulmonary Arterial Hypertension (EFO_0001361), Glioblastoma Multiforme (EFO_0000519), Ulcer Disease (MONDO_0043839), Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717), Congenital Heart Disease (EFO_0005207)', 'newLinkedTargets_string': 'EDNRB (ENSG00000136160), EDNRA (ENSG00000151617)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.45 | Q22 | What is Otezla? | Otezla, also known generically as Apremilast, was approved by the FDA in 2014 to treat Oral ulcer, immune system disease, psoriasis, psoriatic arthritis, and pustulosis palmaris et plantaris. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%otezla%" OR LOWER(tradeNames_string) LIKE "%otezla%" OR LOWER(drugSynonyms_string) LIKE "%otezla%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2487', 'tradeNames_string': 'Otezla', 'drugName': 'Apremilast', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 4 inhibitor', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Rosacea (EFO_1000760), Oral Lichen Planus (EFO_0008517), Pneumonia (EFO_0003106), Ankylosing Spondylitis (EFO_0003898), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Ulcerative Colitis (EFO_0000729), Uveitis (EFO_1001231), Allergic Contact Dermatitis (EFO_1000668), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Oral Ulcer (HP_0000155), Acne (EFO_0003894), Dermatomyositis (EFO_0000398), Immune System Disease (EFO_0000540), Vitiligo (EFO_0004208), Pustulosis Palmaris Et Plantaris (MONDO_0015597), Lichen Planus (EFO_1000726), Influenza (EFO_0007328), Rheumatoid Arthritis (EFO_0000685), Alcohol Dependence (MONDO_0007079), Eczema (HP_0000964), Gout (EFO_0004274), Discoid Lupus Erythematosus (MONDO_0019558), Prostatitis (EFO_0003830), Hidradenitis Suppurativa (EFO_1000710), Dermatitis (MONDO_0002406)", 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.632 | Q22 | What is Testosterone Cypionate? | The drug Testosterone Cypionate was approved by the FDA in 1978 to treat neoplasm, orchitis, and hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%testosterone cypionate%" OR LOWER(tradeNames_string) LIKE "%testosterone cypionate%" OR LOWER(drugSynonyms_string) LIKE "%testosterone cypionate%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_434', 'tradeNames_string': 'Andro-Cyp, Depandro, Depo-testosterone, Depotest, Testosterone, Testosterone cypionate', 'drugName': 'Testosterone Cypionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Prostate Cancer (MONDO_0008315), Diabetic Neuropathy (EFO_1000783), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Sexual Dysfunction (EFO_0004714), Prostate Adenocarcinoma (EFO_0000673), Orchitis (EFO_1001078)', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1978, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.71 | Q22 | What is Giazo? | Giazo, also known generically as Balsalazide Disodium, was approved by the FDA in 2000 to treat ulcerative colitis. It is a small molecule therapy that acts as a(n) agonist and inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%giazo%" OR LOWER(tradeNames_string) LIKE "%giazo%" OR LOWER(drugSynonyms_string) LIKE "%giazo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1296', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugName': 'Balsalazide Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor gamma agonist', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1297', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugName': 'Balsalazide Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1298', 'tradeNames_string': 'Balsalazide disodium, Colazal, Colazide, Giazo', 'drugName': 'Balsalazide Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Arachidonate 5-lipoxygenase inhibitor', 'linkedDiseasesDrug_string': 'Ulcerative Colitis (EFO_0000729)', 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), ALOX5 (ENSG00000012779)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.522 | Q22 | What is Nuplazid? | Nuplazid, also known generically as Pimavanserin Tartrate, was approved by the FDA in 2016 to treat Hallucinations, psychosis, and Parkinson disease. It is a small molecule therapy that acts as a(n) inverse agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nuplazid%" OR LOWER(tradeNames_string) LIKE "%nuplazid%" OR LOWER(drugSynonyms_string) LIKE "%nuplazid%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5097', 'tradeNames_string': 'Nuplazid', 'drugName': 'Pimavanserin Tartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inverse agonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor inverse agonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Alzheimer Disease (MONDO_0004975), Parkinson Disease (MONDO_0005180), Hallucinations (HP_0000738), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2016, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.661 | Q22 | What is Izba? | Izba, also known generically as Travoprost, was approved by the FDA in 2001 to treat glaucoma, open-angle glaucoma, and ocular hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%izba%" OR LOWER(tradeNames_string) LIKE "%izba%" OR LOWER(drugSynonyms_string) LIKE "%izba%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3870', 'tradeNames_string': 'Izba, Travatan, Travatan z, Travoprost', 'drugName': 'Travoprost', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid FP receptor agonist', 'linkedDiseasesDrug_string': 'Exfoliation Syndrome (EFO_0004235), Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.253 | Q22 | What is Tricor? | Tricor, also known generically as Fenofibrate, was approved by the FDA in 1993 to treat Abnormal circulating lipid concentration, Hypercholesterolemia, cardiovascular disease, diabetes mellitus, hypothyroidism, and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tricor%" OR LOWER(tradeNames_string) LIKE "%tricor%" OR LOWER(drugSynonyms_string) LIKE "%tricor%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1497', 'tradeNames_string': 'Antara, Antara (micronized), Fenofibrate, Fenofibrate (micronized), Fenogal, Fenoglide, Lipantil, Lipantil micro 200, Lipantil micro 267, Lipantil micro 67, Lipidil, Lipofen, Supralip 160, Tricor, Tricor (micronized), Triglide', 'drugName': 'Fenofibrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor alpha agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Coronary Artery Disease (EFO_0001645), Multiple Myeloma (EFO_0001378), Combined Hyperlipidemia (Orphanet_79211), Obesity (EFO_0001073), Hypothyroidism (EFO_0004705), Metabolic Disease (EFO_0000589), Primary Biliary Cirrhosis (EFO_1001486), Diabetic Retinopathy (EFO_0003770), Huntington Disease (MONDO_0007739), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Non-Alcoholic Steatohepatitis (EFO_1001249), Disorder Of Lipid Metabolism (Orphanet_309005), Abnormal Circulating Lipid Concentration (HP_0003119), Hypercholesterolemia (HP_0003124), Hiv-1 Infection (EFO_0000180), Hyperlipoproteinemia (MONDO_0037748), Alcohol Dependence (MONDO_0007079), Hyperlipoproteinemia Type 3 (MONDO_0018473), Lipodystrophy (EFO_1000727), Diabetic Nephropathy (EFO_0000401), Burn (EFO_0009516), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), Sclerosing Cholangitis (EFO_0004268)', 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.213 | Q22 | What is Orilissa? | Orilissa, also known generically as Elagolix Sodium, was approved by the FDA in 2018 to treat endometriosis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%orilissa%" OR LOWER(tradeNames_string) LIKE "%orilissa%" OR LOWER(drugSynonyms_string) LIKE "%orilissa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5526', 'tradeNames_string': 'Orilissa', 'drugName': 'Elagolix Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor antagonist', 'linkedDiseasesDrug_string': 'Endometriosis (EFO_0001065)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.168 | Q22 | What is Tafinlar? | Tafinlar, also known generically as Dabrafenib Mesylate, was approved by the FDA in 2013 to treat cutaneous melanoma, melanoma, metastatic melanoma, thyroid carcinoma, and thyroid cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tafinlar%" OR LOWER(tradeNames_string) LIKE "%tafinlar%" OR LOWER(drugSynonyms_string) LIKE "%tafinlar%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_441', 'tradeNames_string': 'Tafinlar', 'drugName': 'Dabrafenib Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': 'Erdheim-Chester Disease (EFO_1000926), Multiple Myeloma (EFO_0001378), Thyroid Carcinoma (EFO_0002892), Melanoma (EFO_0000756), Thyroid Cancer (MONDO_0002108), Metastatic Melanoma (EFO_0002617), Cutaneous Melanoma (EFO_0000389)', 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5089', 'tradeNames_string': 'Tafinlar', 'drugName': 'Dabrafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Liver Disease (EFO_0001421), Metastatic Melanoma (EFO_0002617), Ameloblastoma (MONDO_0017795), Malignant Glioma (MONDO_0100342), Erdheim-Chester Disease (EFO_1000926), Undifferentiated Carcinoma (EFO_0006772), Thyroid Cancer (MONDO_0002108), Brain Neoplasm (EFO_0003833), Cutaneous Melanoma (EFO_0000389), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.476 | Q22 | What is Patanase? | Patanase, also known generically as Olopatadine Hydrochloride, was approved by the FDA in 1996 to treat Pruritus, seasonal allergic rhinitis, allergic rhinitis, and allergic conjunctivitis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%patanase%" OR LOWER(tradeNames_string) LIKE "%patanase%" OR LOWER(drugSynonyms_string) LIKE "%patanase%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6184', 'tradeNames_string': 'Olopatadine hydrochloride, Pataday, Pataday once daily relief, Pataday twice daily relief, Patanase, Patanol, Pazeo', 'drugName': 'Olopatadine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Seasonal Allergic Rhinitis (EFO_0003956), Pruritus (HP_0000989), Allergic Rhinitis (EFO_0005854)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.167 | Q22 | What is Tafinlar? | Tafinlar, also known generically as Dabrafenib, was approved by the FDA in 2013 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tafinlar%" OR LOWER(tradeNames_string) LIKE "%tafinlar%" OR LOWER(drugSynonyms_string) LIKE "%tafinlar%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_441', 'tradeNames_string': 'Tafinlar', 'drugName': 'Dabrafenib Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': 'Erdheim-Chester Disease (EFO_1000926), Multiple Myeloma (EFO_0001378), Thyroid Carcinoma (EFO_0002892), Melanoma (EFO_0000756), Thyroid Cancer (MONDO_0002108), Metastatic Melanoma (EFO_0002617), Cutaneous Melanoma (EFO_0000389)', 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5089', 'tradeNames_string': 'Tafinlar', 'drugName': 'Dabrafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Liver Disease (EFO_0001421), Metastatic Melanoma (EFO_0002617), Ameloblastoma (MONDO_0017795), Malignant Glioma (MONDO_0100342), Erdheim-Chester Disease (EFO_1000926), Undifferentiated Carcinoma (EFO_0006772), Thyroid Cancer (MONDO_0002108), Brain Neoplasm (EFO_0003833), Cutaneous Melanoma (EFO_0000389), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Kidney Disease (EFO_0003086), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.514 | Q22 | What is Pemfexy? | Pemfexy, also known generically as Pemetrexed, was approved by the FDA in 2004 to treat cancer, mesothelioma, neoplasm, malignant pleural mesothelioma, and malignant peritoneal mesothelioma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pemfexy%" OR LOWER(tradeNames_string) LIKE "%pemfexy%" OR LOWER(drugSynonyms_string) LIKE "%pemfexy%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4615', 'tradeNames_string': 'Alimta, Pemfexy', 'drugName': 'Pemetrexed', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dihydrofolate reductase inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Medulloblastoma (EFO_0002939), Thymic Carcinoma (EFO_1000576), Gestational Trophoblastic Neoplasm (MONDO_0018944), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Malignant Peritoneal Mesothelioma (EFO_0005567), Colorectal Neoplasm (EFO_0004142), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Biliary Tract Cancer (MONDO_0003060), Gastric Carcinoma (EFO_0000178), Urethra Cancer (MONDO_0004192), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Bronchoalveolar Adenocarcinoma (EFO_0000308), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Salivary Gland Carcinoma (MONDO_0000521), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Peritoneum Cancer (MONDO_0002087), Large Cell Lung Carcinoma (EFO_0003050), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Leptomeningeal Metastasis (EFO_1001012), Thymoma (EFO_1000581), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Osteosarcoma (EFO_0000637), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Cancer (MONDO_0008903), Chordoma (MONDO_0008978), Sarcoma (EFO_0000691), Nasopharyngeal Neoplasm (EFO_0004252), Malignant Pleural Mesothelioma (EFO_0000770), Stomach Neoplasm (EFO_0003897), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890), DHFR (ENSG00000228716), GART (ENSG00000159131)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4616', 'tradeNames_string': 'Alimta, Pemfexy', 'drugName': 'Pemetrexed', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thymidylate synthase inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Medulloblastoma (EFO_0002939), Thymic Carcinoma (EFO_1000576), Gestational Trophoblastic Neoplasm (MONDO_0018944), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Malignant Peritoneal Mesothelioma (EFO_0005567), Colorectal Neoplasm (EFO_0004142), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Biliary Tract Cancer (MONDO_0003060), Gastric Carcinoma (EFO_0000178), Urethra Cancer (MONDO_0004192), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Bronchoalveolar Adenocarcinoma (EFO_0000308), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Salivary Gland Carcinoma (MONDO_0000521), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Peritoneum Cancer (MONDO_0002087), Large Cell Lung Carcinoma (EFO_0003050), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Leptomeningeal Metastasis (EFO_1001012), Thymoma (EFO_1000581), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Osteosarcoma (EFO_0000637), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Cancer (MONDO_0008903), Chordoma (MONDO_0008978), Sarcoma (EFO_0000691), Nasopharyngeal Neoplasm (EFO_0004252), Malignant Pleural Mesothelioma (EFO_0000770), Stomach Neoplasm (EFO_0003897), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890), DHFR (ENSG00000228716), GART (ENSG00000159131)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4617', 'tradeNames_string': 'Alimta, Pemfexy', 'drugName': 'Pemetrexed', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'GAR transformylase inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Medulloblastoma (EFO_0002939), Thymic Carcinoma (EFO_1000576), Gestational Trophoblastic Neoplasm (MONDO_0018944), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Malignant Peritoneal Mesothelioma (EFO_0005567), Colorectal Neoplasm (EFO_0004142), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Biliary Tract Cancer (MONDO_0003060), Gastric Carcinoma (EFO_0000178), Urethra Cancer (MONDO_0004192), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Bronchoalveolar Adenocarcinoma (EFO_0000308), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Salivary Gland Carcinoma (MONDO_0000521), Thymus Cancer (MONDO_0002586), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Peritoneum Cancer (MONDO_0002087), Large Cell Lung Carcinoma (EFO_0003050), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Leptomeningeal Metastasis (EFO_1001012), Thymoma (EFO_1000581), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Osteosarcoma (EFO_0000637), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Cancer (MONDO_0008903), Chordoma (MONDO_0008978), Sarcoma (EFO_0000691), Nasopharyngeal Neoplasm (EFO_0004252), Malignant Pleural Mesothelioma (EFO_0000770), Stomach Neoplasm (EFO_0003897), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890), DHFR (ENSG00000228716), GART (ENSG00000159131)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.329 | Q22 | What is Kalydeco? | Kalydeco, also known generically as Ivacaftor, was approved by the FDA in 2012 to treat respiratory system disease and cystic fibrosis. It is a small molecule therapy that acts as a(n) positive modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kalydeco%" OR LOWER(tradeNames_string) LIKE "%kalydeco%" OR LOWER(drugSynonyms_string) LIKE "%kalydeco%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5639', 'tradeNames_string': 'Kalydeco', 'drugName': 'Ivacaftor', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive modulator', 'drugMechanismOfAction': 'Cystic fibrosis transmembrane conductance regulator positive modulator', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Chronic Bronchitis (EFO_0006505), Respiratory System Disease (EFO_0000684), Liver Disease (EFO_0001421), Chronic Obstructive Pulmonary Disease (EFO_0000341), Primary Ciliary Dyskinesia (MONDO_0016575), Cystic Fibrosis (MONDO_0009061)', 'newLinkedTargets_string': 'CFTR (ENSG00000001626)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.66 | Q22 | What is Edarbi? | Edarbi, also known generically as Azilsartan Medoxomil, was approved by the FDA in 2011 to treat cardiovascular disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%edarbi%" OR LOWER(tradeNames_string) LIKE "%edarbi%" OR LOWER(drugSynonyms_string) LIKE "%edarbi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5498', 'tradeNames_string': 'Edarbi', 'drugName': 'Azilsartan Medoxomil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Type-1 angiotensin II receptor antagonist', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Essential Hypertension (MONDO_0001134)', 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1209', 'tradeNames_string': 'Edarbi', 'drugName': 'Azilsartan Kamedoxomil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Type-1 angiotensin II receptor antagonist', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Hypertension (EFO_0000537)', 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.415 | Q22 | What is Jornay Pm? | Jornay Pm, also known generically as Methylphenidate Hydrochloride, was approved by the FDA in 1955 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%jornay pm%" OR LOWER(tradeNames_string) LIKE "%jornay pm%" OR LOWER(drugSynonyms_string) LIKE "%jornay pm%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_845', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_846', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.50 | Q22 | What is Aristada Initio Kit? | Aristada Initio Kit, also known generically as Aripiprazole Lauroxil, was approved by the FDA in 2015 to treat autism, Tourette syndrome, bipolar I disorder, major depressive disorder, and schizophrenia. It is a small molecule therapy that acts as a(n) partial agonist and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aristada initio kit%" OR LOWER(tradeNames_string) LIKE "%aristada initio kit%" OR LOWER(drugSynonyms_string) LIKE "%aristada initio kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4679', 'tradeNames_string': 'Aristada, Aristada initio kit', 'drugName': 'Aripiprazole Lauroxil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'partial agonist', 'drugMechanismOfAction': 'Dopamine D2 receptor partial agonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4680', 'tradeNames_string': 'Aristada, Aristada initio kit', 'drugName': 'Aripiprazole Lauroxil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4681', 'tradeNames_string': 'Aristada, Aristada initio kit', 'drugName': 'Aripiprazole Lauroxil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'partial agonist', 'drugMechanismOfAction': 'Serotonin 1a (5-HT1a) receptor partial agonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.121 | Q22 | What is Epidiolex? | Epidiolex, also known generically as Cannabidiol, was approved by the FDA in 2018 to treat Seizure, epilepsy, hamartoma, Lennox-Gastaut syndrome, and Dravet syndrome. It is a small molecule therapy that acts as a(n) negative allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epidiolex%" OR LOWER(tradeNames_string) LIKE "%epidiolex%" OR LOWER(drugSynonyms_string) LIKE "%epidiolex%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4055', 'tradeNames_string': 'Epidiolex', 'drugName': 'Cannabidiol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'negative allosteric modulator', 'drugMechanismOfAction': 'Cannabinoid CB1 receptor negative allosteric modulator', 'linkedDiseasesDrug_string': "Autism (EFO_0003758), Toothache (EFO_0010072), Peripheral Neuropathy (EFO_0003100), Developmental And Epileptic Encephalopathy (MONDO_0100062), Pain (EFO_0003843), Graft Versus Host Disease (MONDO_0013730), Lennox-Gastaut Syndrome (MONDO_0016532), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Covid-19 (MONDO_0100096), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Status Epilepticus (EFO_0008526), Anorexia Nervosa (MONDO_0005351), Intellectual Disability (HP_0001249), Ulcerative Colitis (EFO_0000729), Prostate Adenocarcinoma (EFO_0000673), Neoplasm (EFO_0000616), Post-Traumatic Stress Disorder (EFO_0001358), Osteopenia (HP_0000938), Crohn'S Disease (EFO_0000384), Breast Cancer (MONDO_0007254), Nicotine Dependence (EFO_0003768), Dravet Syndrome (Orphanet_33069), Huntington Disease (MONDO_0007739), Hypertension (EFO_0000537), Schizoaffective Disorder (EFO_0005411), Neuropathic Pain (EFO_0005762), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Psoriatic Arthritis (EFO_0003778), Osteoarthritis, Knee (EFO_0004616), Cocaine Dependence (EFO_0002610), Acute Graft Vs. Host Disease (EFO_0004599), Fibromyalgia (EFO_0005687), Seizure (HP_0001250), Epilepsy (EFO_0000474), Autism Spectrum Disorder (EFO_0003756), Fragile X Syndrome (MONDO_0010383), Sleep Disorder (EFO_0008568), Drug Dependence (EFO_0003890), Obsessive-Compulsive Disorder (EFO_0004242), Benign Essential Blepharospasm (Orphanet_93955), West Syndrome (MONDO_0018097), Childhood Absence Epilepsy (MONDO_0010826), Hiv-1 Infection (EFO_0000180), Hair-Pulling (HP_0012167), Bipolar Disorder (MONDO_0004985), Insomnia (EFO_0004698), Rett Syndrome (MONDO_0010726), Alcohol Dependence (MONDO_0007079), Hepatic Steatosis (HP_0001397), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Opioid Use Disorder (EFO_0010702), Arthralgia (HP_0002829), Hiv Infection (EFO_0000764), Amyotrophic Lateral Sclerosis (MONDO_0004976), Diabetic Neuropathy (EFO_1000783), Essential Tremor (EFO_0003108), Interstitial Cystitis (EFO_0008507), Cognitive Impairment (HP_0100543), Autoimmune Hepatitis (EFO_0005676), Chronic Pain (HP_0012532), Radiculopathy (MONDO_0002959), Lung Cancer (MONDO_0008903), Kidney Disease (EFO_0003086), Hamartoma (EFO_1000634), Osteoarthritis (MONDO_0005178), Heart Failure (EFO_0003144), Sturge-Weber Syndrome (MONDO_0008501), Myocarditis (EFO_0009609), Schizophrenia (MONDO_0005090)", 'newLinkedTargets_string': 'CNR1 (ENSG00000118432)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.195 | Q22 | What is Korsuva? | Korsuva, also known generically as Difelikefalin, was approved by the FDA in 2021 to treat Pruritus and chronic kidney disease. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%korsuva%" OR LOWER(tradeNames_string) LIKE "%korsuva%" OR LOWER(drugSynonyms_string) LIKE "%korsuva%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4408', 'tradeNames_string': 'Korsuva', 'drugName': 'Difelikefalin', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Kappa opioid receptor agonist', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Pruritus (HP_0000989), Osteoarthritis (MONDO_0005178), Pain (EFO_0003843)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.40 | Q22 | What is Evekeo Odt? | Evekeo Odt, also known generically as Amphetamine Sulfate, was approved by the FDA in 1960 to treat attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome. It is a small molecule therapy that acts as a(n) releasing agent. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%evekeo odt%" OR LOWER(tradeNames_string) LIKE "%evekeo odt%" OR LOWER(drugSynonyms_string) LIKE "%evekeo odt%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4795', 'tradeNames_string': 'Amphetamine sulfate, Benzadrine, Evekeo, Evekeo odt', 'drugName': 'Amphetamine Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Norepinephrine transporter releasing agent', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1960, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4796', 'tradeNames_string': 'Amphetamine sulfate, Benzadrine, Evekeo, Evekeo odt', 'drugName': 'Amphetamine Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Dopamine transporter releasing agent', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1960, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.263 | Q22 | What is Children'S Allegra Allergy? | Children'S Allegra Allergy, also known generically as Fexofenadine Hydrochloride, was approved by the FDA in 1996 to treat seasonal allergic rhinitis, urticaria, allergic rhinitis, and allergic disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%children's allegra allergy%" OR LOWER(tradeNames_string) LIKE "%children's allegra allergy%" OR LOWER(drugSynonyms_string) LIKE "%children's allegra allergy%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1045', 'tradeNames_string': "Allegra, Allegra allergy, Allegra hives, Children's allegra allergy, Children's allegra hives, Children's fexofenadine hydrochloride allergy, Children's fexofenadine hydrochloride hives, Fexofenadine hydrochloride, Fexofenadine hydrochloride allergy, Fexofenadine hydrochloride hives, Telfast 120, Telfast 180, Telfast 30", 'drugName': 'Fexofenadine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Allergic Rhinitis (EFO_0005854), Nephrolithiasis (EFO_0004253), Urticaria (EFO_0005531), Allergic Disease (MONDO_0005271)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.428 | Q22 | What is Myrbetriq? | Myrbetriq, also known generically as Mirabegron, was approved by the FDA in 2012 to treat Urinary incontinence, Polyuria, urgency urinary incontinence, and overactive bladder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%myrbetriq%" OR LOWER(tradeNames_string) LIKE "%myrbetriq%" OR LOWER(drugSynonyms_string) LIKE "%myrbetriq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1178', 'tradeNames_string': 'Betmiga, Myrbetriq, Myrbetriq granules', 'drugName': 'Mirabegron', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-3 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Polycystic Ovary Syndrome (EFO_0000660), Chronic Interstitial Cystitis (EFO_1000869), Polyuria (HP_0000103), Intracerebral Hemorrhage (EFO_0005669), Overactive Bladder (EFO_1000781), Left Ventricular Hypertrophy (EFO_0003896), Liver Disease (EFO_0001421), Heart Failure (EFO_0003144), Pain (EFO_0003843), Kidney Disease (EFO_0003086), Prediabetes Syndrome (EFO_1001121), Neurogenic Bladder (HP_0000011), Nephrolithiasis (EFO_0004253), Urinary Incontinence (HP_0000020), Achalasia (HP_0002571)', 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.7 | Q22 | What is Tudorza Pressair? | Tudorza Pressair, also known generically as Aclidinium Bromide, was approved by the FDA in 2012 to treat Airway obstruction, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, and asthma. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tudorza pressair%" OR LOWER(tradeNames_string) LIKE "%tudorza pressair%" OR LOWER(drugSynonyms_string) LIKE "%tudorza pressair%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6136', 'tradeNames_string': 'Eklira, Tudorza pressair', 'drugName': 'Aclidinium Bromide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Nicotine Dependence (EFO_0003768), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.104 | Q22 | What is Cycloset? | Cycloset, also known generically as Bromocriptine Mesylate, was approved by the FDA in 1978 to treat adenoma, infertility, hyperprolactinemia, acromegaly, hypogonadism, type 2 diabetes mellitus, and Parkinson disease. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cycloset%" OR LOWER(tradeNames_string) LIKE "%cycloset%" OR LOWER(drugSynonyms_string) LIKE "%cycloset%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4746', 'tradeNames_string': 'Bromocriptine mesylate, Cycloset, Parlodel', 'drugName': 'Bromocriptine Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'D2-like dopamine receptor agonist', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Acromegaly (EFO_1001485), Infertility (EFO_0000545), Parkinson Disease (MONDO_0005180), Adenoma (EFO_0000232), Type 2 Diabetes Mellitus (MONDO_0005148), Hyperprolactinemia (EFO_0007319)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1978, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.549 | Q22 | What is Tiglutik Kit? | Tiglutik Kit, also known generically as Riluzole, was approved by the FDA in 1995 to treat amyotrophic lateral sclerosis. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tiglutik kit%" OR LOWER(tradeNames_string) LIKE "%tiglutik kit%" OR LOWER(drugSynonyms_string) LIKE "%tiglutik kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2334', 'tradeNames_string': 'Exservan, Rilutek, Riluzole, Teglutik, Tiglutik kit', 'drugName': 'Riluzole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Peripheral Neuropathy (EFO_0003100), Multiple Sclerosis (MONDO_0005301), Cerebellar Ataxia (MONDO_0000437), Spinal Cord Injury (EFO_1001919), Atrial Fibrillation (EFO_0000275), Post-Traumatic Stress Disorder (EFO_0001358), Breast Cancer (MONDO_0007254), Huntington Disease (MONDO_0007739), Spinal Muscular Atrophy (EFO_0008525), Multiple System Atrophy (EFO_1001050), Autism Spectrum Disorder (EFO_0003756), Secondary Progressive Multiple Sclerosis (EFO_0008522), Myelopathy (HP_0002196), Obsessive-Compulsive Disorder (EFO_0004242), Progressive Supranuclear Palsy (MONDO_0019037), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Cutaneous Melanoma (EFO_0000389), Spinocerebellar Ataxia Type 2 (MONDO_0008458), Amyotrophic Lateral Sclerosis (MONDO_0004976), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.303 | Q22 | What is Supprelin La? | Supprelin La, also known generically as Histrelin Acetate, was approved by the FDA in 1991 to treat prostate adenocarcinoma and prostate cancer. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%supprelin la%" OR LOWER(tradeNames_string) LIKE "%supprelin la%" OR LOWER(drugSynonyms_string) LIKE "%supprelin la%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3420', 'tradeNames_string': 'Supprelin, Supprelin la, Vantas', 'drugName': 'Histrelin Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1991, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.401 | Q22 | What is Anjeso? | Anjeso, also known generically as Meloxicam, was approved by the FDA in 2000 to treat rheumatoid arthritis, juvenile idiopathic arthritis, rheumatic disease, and osteoarthritis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anjeso%" OR LOWER(tradeNames_string) LIKE "%anjeso%" OR LOWER(drugSynonyms_string) LIKE "%anjeso%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_988', 'tradeNames_string': 'Anjeso, Meloxicam, Mobic, Qmiiz odt, Vivlodex', 'drugName': 'Meloxicam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase-2 inhibitor', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Rheumatic Disease (EFO_0005755), Pharyngitis (MONDO_0002258), Osteoarthritis (MONDO_0005178), Juvenile Idiopathic Arthritis (EFO_0002609), Ankylosing Spondylitis (EFO_0003898), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Tuberculosis (MONDO_0018076), Dysmenorrhea (HP_0100607), Systemic Lupus Erythematosus (MONDO_0007915), Shoulder Pain (HP_0030834), Low Back Pain (HP_0003419), Rheumatoid Arthritis (EFO_0000685), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.508 | Q22 | What is Votrient? | Votrient, also known generically as Pazopanib, was approved by the FDA in 2009 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%votrient%" OR LOWER(tradeNames_string) LIKE "%votrient%" OR LOWER(drugSynonyms_string) LIKE "%votrient%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_385', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor 1 inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_386', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase LCK inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_387', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor 3 inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_388', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_389', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_390', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ITK/TSK inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_391', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_392', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Macrophage colony stimulating factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Collecting Duct Carcinoma (EFO_0003016), Prostate Carcinoma (EFO_0001663), Angiosarcoma (EFO_0003968), Ovarian Cancer (MONDO_0008170), Gliosarcoma (EFO_1001465), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Von Hippel-Lindau Disease (MONDO_0008667), Cutaneous Melanoma (EFO_0000389), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Follicular Thyroid Carcinoma (EFO_0000501)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), LCK (ENSG00000182866)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5653', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor 1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Lymphedema (MONDO_0019297), Macular Degeneration (EFO_0009606), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Gastrointestinal Stromal Tumor (MONDO_0011719), Collecting Duct Carcinoma (EFO_0003016), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Prostate Adenocarcinoma (EFO_0000673), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Urethra Cancer (MONDO_0004192), Dermatofibrosarcoma Protuberans (MONDO_0011934), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Solitary Fibrous Tumor (MONDO_0016238), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Chondrosarcoma (EFO_0000333), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Leiomyosarcoma (EFO_0000564), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Colorectal Adenocarcinoma (EFO_0000365), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5654', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase LCK inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Lymphedema (MONDO_0019297), Macular Degeneration (EFO_0009606), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Gastrointestinal Stromal Tumor (MONDO_0011719), Collecting Duct Carcinoma (EFO_0003016), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Prostate Adenocarcinoma (EFO_0000673), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Urethra Cancer (MONDO_0004192), Dermatofibrosarcoma Protuberans (MONDO_0011934), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Solitary Fibrous Tumor (MONDO_0016238), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Chondrosarcoma (EFO_0000333), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Leiomyosarcoma (EFO_0000564), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Colorectal Adenocarcinoma (EFO_0000365), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5655', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor 3 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Lymphedema (MONDO_0019297), Macular Degeneration (EFO_0009606), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Gastrointestinal Stromal Tumor (MONDO_0011719), Collecting Duct Carcinoma (EFO_0003016), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Prostate Adenocarcinoma (EFO_0000673), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Urethra Cancer (MONDO_0004192), Dermatofibrosarcoma Protuberans (MONDO_0011934), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Solitary Fibrous Tumor (MONDO_0016238), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Chondrosarcoma (EFO_0000333), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Leiomyosarcoma (EFO_0000564), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Colorectal Adenocarcinoma (EFO_0000365), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5656', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Lymphedema (MONDO_0019297), Macular Degeneration (EFO_0009606), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Gastrointestinal Stromal Tumor (MONDO_0011719), Collecting Duct Carcinoma (EFO_0003016), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Prostate Adenocarcinoma (EFO_0000673), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Urethra Cancer (MONDO_0004192), Dermatofibrosarcoma Protuberans (MONDO_0011934), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Solitary Fibrous Tumor (MONDO_0016238), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Chondrosarcoma (EFO_0000333), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Leiomyosarcoma (EFO_0000564), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Colorectal Adenocarcinoma (EFO_0000365), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5657', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Lymphedema (MONDO_0019297), Macular Degeneration (EFO_0009606), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Gastrointestinal Stromal Tumor (MONDO_0011719), Collecting Duct Carcinoma (EFO_0003016), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Prostate Adenocarcinoma (EFO_0000673), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Urethra Cancer (MONDO_0004192), Dermatofibrosarcoma Protuberans (MONDO_0011934), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Solitary Fibrous Tumor (MONDO_0016238), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Chondrosarcoma (EFO_0000333), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Leiomyosarcoma (EFO_0000564), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Colorectal Adenocarcinoma (EFO_0000365), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5658', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ITK/TSK inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Lymphedema (MONDO_0019297), Macular Degeneration (EFO_0009606), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Gastrointestinal Stromal Tumor (MONDO_0011719), Collecting Duct Carcinoma (EFO_0003016), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Prostate Adenocarcinoma (EFO_0000673), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Urethra Cancer (MONDO_0004192), Dermatofibrosarcoma Protuberans (MONDO_0011934), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Solitary Fibrous Tumor (MONDO_0016238), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Chondrosarcoma (EFO_0000333), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Leiomyosarcoma (EFO_0000564), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Colorectal Adenocarcinoma (EFO_0000365), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5659', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Lymphedema (MONDO_0019297), Macular Degeneration (EFO_0009606), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Gastrointestinal Stromal Tumor (MONDO_0011719), Collecting Duct Carcinoma (EFO_0003016), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Prostate Adenocarcinoma (EFO_0000673), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Urethra Cancer (MONDO_0004192), Dermatofibrosarcoma Protuberans (MONDO_0011934), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Solitary Fibrous Tumor (MONDO_0016238), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Chondrosarcoma (EFO_0000333), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Leiomyosarcoma (EFO_0000564), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Colorectal Adenocarcinoma (EFO_0000365), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5660', 'tradeNames_string': 'Votrient', 'drugName': 'Pazopanib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Macrophage colony stimulating factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Lymphedema (MONDO_0019297), Macular Degeneration (EFO_0009606), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Gastrointestinal Stromal Tumor (MONDO_0011719), Collecting Duct Carcinoma (EFO_0003016), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Prostate Adenocarcinoma (EFO_0000673), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Urethra Cancer (MONDO_0004192), Dermatofibrosarcoma Protuberans (MONDO_0011934), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Solitary Fibrous Tumor (MONDO_0016238), Salivary Gland Carcinoma (MONDO_0000521), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Chondrosarcoma (EFO_0000333), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Leiomyosarcoma (EFO_0000564), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Colorectal Adenocarcinoma (EFO_0000365), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Alveolar Soft Part Sarcoma (EFO_0007143), Von Hippel-Lindau Disease (MONDO_0008667), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ITK (ENSG00000113263), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), KIT (ENSG00000157404), CSF1R (ENSG00000182578), LCK (ENSG00000182866), FGFR1 (ENSG00000077782)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.323 | Q22 | What is Atrovent Hfa? | Atrovent Hfa, also known generically as Ipratropium Bromide, was approved by the FDA in 1986 to treat Nasal congestion, Airway obstruction, Bronchospasm, atopic eczema, chronic obstructive pulmonary disease, emphysema, seasonal allergic rhinitis, chronic bronchitis, common cold, and asthma. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atrovent hfa%" OR LOWER(tradeNames_string) LIKE "%atrovent hfa%" OR LOWER(drugSynonyms_string) LIKE "%atrovent hfa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4927', 'tradeNames_string': 'Atrovent, Atrovent aerocaps, Atrovent fte, Atrovent hfa, Atrovent udvs, Ipratrop, Ipratrop steripoule, Ipratropium bromide, Respontin, Rinatec, Tropiovent', 'drugName': 'Ipratropium Bromide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Nasal Congestion (HP_0001742), Chronic Bronchitis (EFO_0006505), Bronchospasm (HP_0025428), Common Cold (EFO_0007214), Asthma (MONDO_0004979), Seasonal Allergic Rhinitis (EFO_0003956), Atopic Eczema (EFO_0000274), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Parkinson Disease (MONDO_0005180), Pulmonary Arterial Hypertension (EFO_0001361), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464), Familial Dysautonomia (Orphanet_1764)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1986, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.148 | Q22 | What is Nexiclon Xr? | Nexiclon Xr, also known generically as Clonidine, was approved by the FDA in 1974 to treat cancer, glaucoma, hypertension, attention deficit hyperactivity disorder, neuropathic pain, and migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nexiclon xr%" OR LOWER(tradeNames_string) LIKE "%nexiclon xr%" OR LOWER(drugSynonyms_string) LIKE "%nexiclon xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_615', 'tradeNames_string': 'Catapres, Catapres-tts-1, Catapres-tts-2, Catapres-tts-3, Clonidine, Nexiclon xr', 'drugName': 'Clonidine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-2 agonist', 'linkedDiseasesDrug_string': 'Fecal Incontinence (EFO_0009523), Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Hemorrhage (MP_0001914), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Neonatal Abstinence Syndrome (EFO_0005799), Cannabis Dependence (EFO_0007191), Male Reproductive Organ Cancer (EFO_0007355), Glaucoma (MONDO_0005041), Musculoskeletal System Disease (EFO_0009676), Pregnancy (EFO_0002950), Post-Traumatic Stress Disorder (EFO_0001358), Breast Cancer (MONDO_0007254), Atopic Eczema (EFO_0000274), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Attention Deficit Hyperactivity Disorder (EFO_0003888), Scoliosis (EFO_0004273), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Heroin Dependence (EFO_0004240), Drug Dependence (EFO_0003890), Delirium (EFO_0009267), Orthostatic Intolerance (EFO_1000645), Hyperemesis Gravidarum (EFO_1000971), Brain Injury (MONDO_0043510), Opioid Dependence (EFO_0005611), Diabetic Neuropathy (EFO_1000783), Post-Operative Sign Or Symptom (EFO_0005323), Low Back Pain (HP_0003419), Oral Mucositis (EFO_1001904)', 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1974, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.493 | Q22 | What is Opana Er? | Opana Er, also known generically as Oxymorphone Hydrochloride, was approved by the FDA in 1959 to treat pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%opana er%" OR LOWER(tradeNames_string) LIKE "%opana er%" OR LOWER(drugSynonyms_string) LIKE "%opana er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4591', 'tradeNames_string': 'Numorphan, Opana, Opana er, Oxymorphone hydrochloride', 'drugName': 'Oxymorphone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta agonist', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1959, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.359 | Q22 | What is Fetzima? | Fetzima, also known generically as Levomilnacipran, was approved by the FDA in 2013 to treat unipolar depression. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fetzima%" OR LOWER(tradeNames_string) LIKE "%fetzima%" OR LOWER(drugSynonyms_string) LIKE "%fetzima%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5567', 'tradeNames_string': 'Fetzima', 'drugName': 'Levomilnacipran Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Fibromyalgia (EFO_0005687), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Ischemic Stroke (HP_0002140)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5568', 'tradeNames_string': 'Fetzima', 'drugName': 'Levomilnacipran Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Fibromyalgia (EFO_0005687), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Ischemic Stroke (HP_0002140)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4419', 'tradeNames_string': 'Fetzima', 'drugName': 'Levomilnacipran', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Ischemic Stroke (HP_0002140), Nicotine Dependence (EFO_0003768), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4420', 'tradeNames_string': 'Fetzima', 'drugName': 'Levomilnacipran', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Ischemic Stroke (HP_0002140), Nicotine Dependence (EFO_0003768), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.212 | Q22 | What is Savaysa? | Savaysa, also known generically as Edoxaban Tosylate, was approved by the FDA in 2015 to treat atrial fibrillation, stroke, pulmonary embolism, and deep vein thrombosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%savaysa%" OR LOWER(tradeNames_string) LIKE "%savaysa%" OR LOWER(drugSynonyms_string) LIKE "%savaysa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5025', 'tradeNames_string': 'Savaysa', 'drugName': 'Edoxaban Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Coagulation factor X inhibitor', 'linkedDiseasesDrug_string': 'Stroke (EFO_0000712), Deep Vein Thrombosis (EFO_0003907), Venous Thromboembolism (EFO_0004286), Thrombotic Disease (MONDO_0000831), Pulmonary Embolism (EFO_0003827), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'F10 (ENSG00000126218)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.702 | Q22 | What is Prialt? | Prialt, also known generically as Ziconotide Acetate, was approved by the FDA in 2004 to treat Fever and pain. It is a protein therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prialt%" OR LOWER(tradeNames_string) LIKE "%prialt%" OR LOWER(drugSynonyms_string) LIKE "%prialt%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2513', 'tradeNames_string': 'Prialt', 'drugName': 'Ziconotide', 'drugMolecularType': 'Protein', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated N-type calcium channel alpha-1B subunit blocker', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Fever (HP_0001945)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4779', 'tradeNames_string': 'Prialt', 'drugName': 'Ziconotide Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated N-type calcium channel alpha-1B subunit blocker', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Fever (HP_0001945)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.367 | Q22 | What is Levothyroxine Sodium? | The drug Levothyroxine Sodium was approved by the FDA in 2000 to treat thyroid carcinoma, hypothyroidism, differentiated thyroid carcinoma, thyroid cancer, and congenital hypothyroidism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levothyroxine sodium%" OR LOWER(tradeNames_string) LIKE "%levothyroxine sodium%" OR LOWER(drugSynonyms_string) LIKE "%levothyroxine sodium%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_83', 'tradeNames_string': 'Cytomel, Tertroxin', 'drugName': 'Liothyronine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Myxedema (EFO_1001055), Multiple Sclerosis (MONDO_0005301), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017), Abnormality Of Cardiovascular System Morphology (HP_0030680), Atrial Fibrillation (EFO_0000275), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Septic Shock (EFO_0006834), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Thyroid Neoplasm (EFO_0003841), Chronic Progressive Multiple Sclerosis (EFO_0003840), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Euthyroid Sick Syndrome (EFO_1000931), Congenital Heart Disease (EFO_0005207), Head And Neck Malignant Neoplasia (EFO_0006859), Unipolar Depression (EFO_0003761), Heart Failure (EFO_0003144)', 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1956, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5964', 'tradeNames_string': 'Eltroxin, Ermeza, Euthyrox, Evotrox, L-thyroxine henning, Levo-t, Levolet, Levothroid, Levothyroid, Levothyroxine sodium, Levoxine, Levoxyl, Novothyrox, Soloxine, Synthroid, Thyquidity, Thyro-tabs, Thyrol L, Thyroxine, Tirosint, Tirosint-sol, Unithroid', 'drugName': 'Levothyroxine Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Congenital Hypothyroidism (MONDO_0018612), Pain (EFO_0003843), Thyroid Carcinoma (EFO_0002892), Thyroid Cancer (MONDO_0002108), Bipolar Disorder (MONDO_0004985), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017)', 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.89 | Q22 | What is Angiomax? | Angiomax, also known generically as Bivalirudin, was approved by the FDA in 2000 to treat Thrombocytopenia, Recurrent thrombophlebitis, intermediate coronary syndrome, thrombotic disease, and syndromic disease. It is a protein therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%angiomax%" OR LOWER(tradeNames_string) LIKE "%angiomax%" OR LOWER(drugSynonyms_string) LIKE "%angiomax%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4317', 'tradeNames_string': 'Angiomax, Angiomax rtu, Bivalirudin, Bivalirudin in 0.9% sodium chloride', 'drugName': 'Bivalirudin', 'drugMolecularType': 'Protein', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thrombin inhibitor', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Thrombocytopenia (HP_0001873), Heart Disease (EFO_0003777), Coronary Artery Disease (EFO_0001645), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Aortic Stenosis (EFO_0000266), Hemorrhage (MP_0001914), Deep Vein Thrombosis (EFO_0003907), Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612), Subarachnoid Hemorrhage (EFO_0000713), Acute Myocardial Infarction (EFO_0008583), Acute Coronary Syndrome (EFO_0005672), Thrombotic Disease (MONDO_0000831), Intermediate Coronary Syndrome (EFO_1000985)', 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.671 | Q22 | What is Trelstar? | Trelstar, also known generically as Triptorelin Pamoate, was approved by the FDA in 2000 to treat prostate adenocarcinoma, prostate carcinoma, Central precocious puberty, and precocious puberty. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trelstar%" OR LOWER(tradeNames_string) LIKE "%trelstar%" OR LOWER(drugSynonyms_string) LIKE "%trelstar%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4710', 'tradeNames_string': 'Trelstar, Triptodur kit', 'drugName': 'Triptorelin Pamoate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Central Precocious Puberty (EFO_0009029), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Endometriosis (EFO_0001065), Precocious Puberty (MONDO_0000088), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.488 | Q22 | What is Oxaydo? | Oxaydo, also known generically as Oxycodone Hydrochloride, was approved by the FDA in 1950 to treat Chronic pain and pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxaydo%" OR LOWER(tradeNames_string) LIKE "%oxaydo%" OR LOWER(drugSynonyms_string) LIKE "%oxaydo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4049', 'tradeNames_string': 'Abtard, Candox, Carexil, Dolocodon pr, Leveraxo, Longtec, Lynlor, Oxaydo, Oxecta, Oxeltra, Oxycodone hydrochloride, Oxycontin, Oxylan, Oxynorm, Reltebon, Roxicodone, Roxybond, Shortec, Zomestine', 'drugName': 'Oxycodone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Osteoarthritis, Hip (EFO_1000786), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1950, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.640 | Q22 | What is Spiriva? | Spiriva, also known generically as Tiotropium Bromide, was approved by the FDA in 2004 to treat Airway obstruction, Bronchospasm, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, and asthma. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%spiriva%" OR LOWER(tradeNames_string) LIKE "%spiriva%" OR LOWER(drugSynonyms_string) LIKE "%spiriva%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4878', 'tradeNames_string': 'Spiriva, Spiriva respimat', 'drugName': 'Tiotropium Bromide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Neoplasm (EFO_0000616), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Cystic Fibrosis (MONDO_0009061), Renal Insufficiency (HP_0000083), Emphysema (EFO_0000464), Spinal Cord Injury (EFO_1001919)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_547', 'tradeNames_string': 'Braltus, Spiriva, Spiriva respimat', 'drugName': 'Tiotropium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Neoplasm (EFO_0000616), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Cystic Fibrosis (MONDO_0009061), Renal Insufficiency (HP_0000083), Emphysema (EFO_0000464), Spinal Cord Injury (EFO_1001919)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.42 | Q22 | What is Erleada? | Erleada, also known generically as Apalutamide, was approved by the FDA in 2018 to treat metastatic prostate cancer, cancer, neoplasm, prostate adenocarcinoma, prostate carcinoma, and prostate cancer. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%erleada%" OR LOWER(tradeNames_string) LIKE "%erleada%" OR LOWER(drugSynonyms_string) LIKE "%erleada%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6164', 'tradeNames_string': 'Erleada', 'drugName': 'Apalutamide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Androgen Receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Liver Disease (EFO_0001421), Metastatic Prostate Cancer (EFO_0000196), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.111 | Q22 | What is Jevtana Kit? | Jevtana Kit, also known generically as Cabazitaxel, was approved by the FDA in 2010 to treat metastatic prostate cancer, cancer, neoplasm, prostate adenocarcinoma, prostate carcinoma, and prostate cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%jevtana kit%" OR LOWER(tradeNames_string) LIKE "%jevtana kit%" OR LOWER(drugSynonyms_string) LIKE "%jevtana kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_762', 'tradeNames_string': 'Jevtana, Jevtana kit', 'drugName': 'Cabazitaxel', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Penile Neoplasm (EFO_1001094), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Dedifferentiated Liposarcoma (EFO_0003085), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Transitional Cell Carcinoma (EFO_1000601), Metastatic Prostate Cancer (EFO_0000196), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.697 | Q22 | What is Voxzogo? | Voxzogo, also known generically as Vosoritide, was approved by the FDA in 2021 to treat bone disease and achondroplasia. It is a protein therapy that acts as a(n) binding agent. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%voxzogo%" OR LOWER(tradeNames_string) LIKE "%voxzogo%" OR LOWER(drugSynonyms_string) LIKE "%voxzogo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6124', 'tradeNames_string': 'Voxzogo', 'drugName': 'Vosoritide', 'drugMolecularType': 'Protein', 'drugActionType': 'binding agent', 'drugMechanismOfAction': 'Atrial natriuretic peptide receptor B binding agent', 'linkedDiseasesDrug_string': 'Achondroplasia (MONDO_0007037), Bone Disease (EFO_0004260)', 'newLinkedTargets_string': 'NPR2 (ENSG00000159899)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.57 | Q22 | What is Stendra? | Stendra, also known generically as Avanafil, was approved by the FDA in 2011 to treat erectile dysfunction. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%stendra%" OR LOWER(tradeNames_string) LIKE "%stendra%" OR LOWER(drugSynonyms_string) LIKE "%stendra%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5497', 'tradeNames_string': 'Spedra, Stendra', 'drugName': 'Avanafil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 5A inhibitor', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Erectile Dysfunction (EFO_0004234)', 'newLinkedTargets_string': 'PDE5A (ENSG00000138735)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.430 | Q22 | What is Pyrukynd? | Pyrukynd, also known generically as Mitapivat Sulfate, was approved by the FDA in 2022 to treat familial hemolytic anemia. It is a small molecule therapy that acts as a(n) activator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pyrukynd%" OR LOWER(tradeNames_string) LIKE "%pyrukynd%" OR LOWER(drugSynonyms_string) LIKE "%pyrukynd%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2811', 'tradeNames_string': 'Pyrukynd', 'drugName': 'Mitapivat Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'activator', 'drugMechanismOfAction': 'Pyruvate kinase isozymes R/L activator', 'linkedDiseasesDrug_string': 'Familial Hemolytic Anemia (MONDO_0003689)', 'newLinkedTargets_string': 'PKLR (ENSG00000143627)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.521 | Q22 | What is Phenylephrine Hydrochloride? | The drug Phenylephrine Hydrochloride was approved by the FDA in 1952 to treat Pruritus, Nasal congestion, seasonal allergic rhinitis, hypotension, septic shock, common cold, sinusitis, hemorrhoid, and allergic disease. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenylephrine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%phenylephrine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%phenylephrine hydrochloride%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3941', 'tradeNames_string': 'Afrin 4 hour nasal spray, Biomydrin, Biorphen, Fenilfar, Fenox, Mydfrin, Nazex, Neo-synephrine, Neosynephrine, Nostril, Nurofen sinus pain relief, Phenylephrine hydrochloride, Prefrin, Vazculep', 'drugName': 'Phenylephrine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-1 agonist', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Common Cold (EFO_0007214), Acute Lung Injury (EFO_0004610), Infection (EFO_0000544), Hypotension (EFO_0005251), Septic Shock (EFO_0006834), Seasonal Allergic Rhinitis (EFO_0003956), Hemorrhoid (EFO_0009552), Cataract (MONDO_0005129), Cardiovascular Disease (EFO_0000319), Cardiac Arrhythmia (EFO_0004269), Vasomotor Rhinitis (EFO_0007533), Respiratory Tract Infectious Disorder (MONDO_0024355), Nasal Congestion (HP_0001742), Allergic Disease (MONDO_0005271), Gastric Carcinoma (EFO_0000178), Pruritus (HP_0000989), Rhinitis (EFO_0008521)', 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1952, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.25 | Q22 | What is Piqray? | Piqray, also known generically as Alpelisib, was approved by the FDA in 2019 to treat breast carcinoma, cancer, neoplasm, breast neoplasm, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%piqray%" OR LOWER(tradeNames_string) LIKE "%piqray%" OR LOWER(drugSynonyms_string) LIKE "%piqray%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_722', 'tradeNames_string': 'Piqray, Vijoice', 'drugName': 'Alpelisib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PI3-kinase p110-alpha subunit inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Gastrointestinal Stromal Tumor (MONDO_0011719), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Oropharynx Cancer (EFO_1001931), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Rectum Cancer (EFO_1000657), Squamous Cell Carcinoma (EFO_0000707), Esophageal Squamous Cell Carcinoma (EFO_0005922), Neoplasm (EFO_0000616), Meningioma (MONDO_0016642)', 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.222 | Q22 | What is Braftovi? | Braftovi, also known generically as Encorafenib, was approved by the FDA in 2018 to treat cancer, cutaneous melanoma, neoplasm, melanoma, and metastatic melanoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%braftovi%" OR LOWER(tradeNames_string) LIKE "%braftovi%" OR LOWER(drugSynonyms_string) LIKE "%braftovi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3616', 'tradeNames_string': 'Braftovi', 'drugName': 'Encorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Rectum Cancer (EFO_1000657), Multiple Myeloma (EFO_0001378), Neoplasm (EFO_0000616), Thyroid Carcinoma (EFO_0002892), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Adenocarcinoma (EFO_0000365), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Metastatic Melanoma (EFO_0002617), Hairy Cell Leukemia (EFO_1000956), Colorectal Carcinoma (EFO_1001951), Cutaneous Melanoma (EFO_0000389)', 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.437 | Q22 | What is Arymo Er? | Arymo Er, also known generically as Morphine Sulfate, was approved by the FDA in 1984 to treat Chronic pain, cancer, pain, and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%arymo er%" OR LOWER(tradeNames_string) LIKE "%arymo er%" OR LOWER(drugSynonyms_string) LIKE "%arymo er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3650', 'tradeNames_string': 'Arymo er, Astramorph pf, Avinza, Depodur, Duramorph, Duramorph pf, Duromorph, Filnarine sr, Infumorph, Kadian, Moraxen, Morcap sr, Morphabond, Morphabond er, Morphgesic sr, Morphine sulfate, Morphine sulfate (autoinjector), Ms contin, Mst continus, Oramorph, Oramorph sr, Oramorph udv, Rhotard, Sevredol, Srm-rhotard, Zomorph', 'drugName': 'Morphine Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Neonatal Abstinence Syndrome (EFO_0005799), Chronic Pain (HP_0012532), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616), Myocardial Infarction (EFO_0000612), Pulmonary Arterial Hypertension (EFO_0001361), Sickle Cell Anemia (MONDO_0011382), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419), Obstructive Sleep Apnea (EFO_0003918), Idiopathic Pulmonary Fibrosis (EFO_0000768), Pruritus (HP_0000989), Opioid Dependence (EFO_0005611)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.285 | Q22 | What is Givlaari? | Givlaari, also known generically as Givosiran Sodium, was approved by the FDA in 2019 to treat liver disease and Acute hepatic porphyria. It is a oligonucleotide therapy that acts as a(n) rnai inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%givlaari%" OR LOWER(tradeNames_string) LIKE "%givlaari%" OR LOWER(drugSynonyms_string) LIKE "%givlaari%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5803', 'tradeNames_string': 'Givlaari', 'drugName': 'Givosiran Sodium', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'rnai inhibitor', 'drugMechanismOfAction': '5-aminolevulinate synthase mRNA RNAi inhibitor', 'linkedDiseasesDrug_string': 'Acute Hepatic Porphyria (Orphanet_95157), Liver Disease (EFO_0001421)', 'newLinkedTargets_string': 'ALAS1 (ENSG00000023330)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.113 | Q22 | What is Cometriq? | Cometriq, also known generically as Cabozantinib, was approved by the FDA in 2012 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cometriq%" OR LOWER(tradeNames_string) LIKE "%cometriq%" OR LOWER(drugSynonyms_string) LIKE "%cometriq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3579', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib S-Malate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3580', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib S-Malate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4806', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Intrahepatic Cholangiocarcinoma (EFO_1001961), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Neuroendocrine Carcinoma (MONDO_0002120), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Papillary Renal Cell Carcinoma (EFO_0000640), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Anaplastic Astrocytoma (EFO_0002499), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Endometrial Carcinoma (EFO_1001512), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Osteosarcoma (EFO_0000637), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Meningioma (MONDO_0016642), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4807', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Intrahepatic Cholangiocarcinoma (EFO_1001961), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Neuroendocrine Carcinoma (MONDO_0002120), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Papillary Renal Cell Carcinoma (EFO_0000640), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Anaplastic Astrocytoma (EFO_0002499), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Endometrial Carcinoma (EFO_1001512), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Osteosarcoma (EFO_0000637), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Meningioma (MONDO_0016642), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.85 | Q22 | What is Durysta? | Durysta, also known generically as Bimatoprost, was approved by the FDA in 2001 to treat glaucoma, open-angle glaucoma, ocular hypertension, hypotrichosis, and hypotrichosis simplex. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%durysta%" OR LOWER(tradeNames_string) LIKE "%durysta%" OR LOWER(drugSynonyms_string) LIKE "%durysta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_704', 'tradeNames_string': 'Bimatoprost, Durysta, Latisse, Lumigan', 'drugName': 'Bimatoprost', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid FP receptor agonist', 'linkedDiseasesDrug_string': 'Androgenetic Alopecia (EFO_0004191), Vitiligo (EFO_0004208), Graves Ophthalmopathy (EFO_1001466), Alopecia (MONDO_0004907), Hypotrichosis (MONDO_0003037), Open-Angle Glaucoma (EFO_0004190), Hypotrichosis Simplex (MONDO_0018914), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.52 | Q22 | What is Scemblix? | Scemblix, also known generically as Asciminib Hydrochloride, was approved by the FDA in 2021 to treat chronic myelogenous leukemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%scemblix%" OR LOWER(tradeNames_string) LIKE "%scemblix%" OR LOWER(drugSynonyms_string) LIKE "%scemblix%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4114', 'tradeNames_string': 'Scemblix', 'drugName': 'Asciminib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein inhibitor', 'linkedDiseasesDrug_string': 'Chronic Myelogenous Leukemia (EFO_0000339)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.224 | Q22 | What is Xtandi? | Xtandi, also known generically as Enzalutamide, was approved by the FDA in 2012 to treat metastatic prostate cancer, cancer, neoplasm, prostate adenocarcinoma, prostate carcinoma, and prostate cancer. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xtandi%" OR LOWER(tradeNames_string) LIKE "%xtandi%" OR LOWER(drugSynonyms_string) LIKE "%xtandi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4352', 'tradeNames_string': 'Xtandi', 'drugName': 'Enzalutamide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Androgen Receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Liver Disease (EFO_0001421), Covid-19 (MONDO_0100096), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Pancreatic Carcinoma (EFO_0002618), Clear Cell Renal Carcinoma (EFO_0000349), Carcinoma (EFO_0000313), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Metastatic Prostate Cancer (EFO_0000196), Kidney Disease (EFO_0003086)', 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.566 | Q22 | What is Banzel? | Banzel, also known generically as Rufinamide, was approved by the FDA in 2008 to treat Seizure, epilepsy, and Lennox-Gastaut syndrome. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%banzel%" OR LOWER(tradeNames_string) LIKE "%banzel%" OR LOWER(drugSynonyms_string) LIKE "%banzel%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5349', 'tradeNames_string': 'Banzel, Inovelon, Rufinamide', 'drugName': 'Rufinamide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Epilepsy (EFO_0000474), Lennox-Gastaut Syndrome (MONDO_0016532), Seizure (HP_0001250)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.551 | Q22 | What is Adempas? | Adempas, also known generically as Riociguat, was approved by the FDA in 2013 to treat hypertension, pulmonary arterial hypertension, pulmonary hypertension, and idiopathic and/or familial pulmonary arterial hypertension. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%adempas%" OR LOWER(tradeNames_string) LIKE "%adempas%" OR LOWER(drugSynonyms_string) LIKE "%adempas%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3991', 'tradeNames_string': 'Adempas, Bay 63-2521', 'drugName': 'Riociguat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'Soluble guanylate cyclase positive allosteric modulator', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Hiv Infection (EFO_0000764), Pulmonary Hypertension (MONDO_0005149), Hypertension (EFO_0000537), Raynaud Disease (EFO_1001145), Sickle Cell Anemia (MONDO_0011382), Idiopathic And/Or Familial Pulmonary Arterial Hypertension (MONDO_0008347), Pulmonary Arterial Hypertension (EFO_0001361), Cystic Fibrosis (MONDO_0009061), Ulcer Disease (MONDO_0043839), Systemic Scleroderma (EFO_0000717), Scleroderma (EFO_1001993)', 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.306 | Q22 | What is Zohydro Er? | Zohydro Er, also known generically as Hydrocodone Bitartrate, was approved by the FDA in 1943 to treat pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zohydro er%" OR LOWER(tradeNames_string) LIKE "%zohydro er%" OR LOWER(drugSynonyms_string) LIKE "%zohydro er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2476', 'tradeNames_string': 'Dicodid, Hysingla, Hysingla er, Mercodinone, Vantrela er, Zohydro er', 'drugName': 'Hydrocodone Bitartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta agonist', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890), Osteoarthritis (MONDO_0005178), Rotator Cuff Tear (EFO_1001250), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Kidney Disease (EFO_0003086), Injury (EFO_0000546), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1943, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.559 | Q22 | What is Zoryve? | Zoryve, also known generically as Roflumilast, was approved by the FDA in 2011 to treat Airway obstruction, chronic obstructive pulmonary disease, and chronic bronchitis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zoryve%" OR LOWER(tradeNames_string) LIKE "%zoryve%" OR LOWER(drugSynonyms_string) LIKE "%zoryve%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5055', 'tradeNames_string': 'Daliresp, Daxas, Zoryve', 'drugName': 'Roflumilast', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 4 inhibitor', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Cancer (MONDO_0004992), Rosacea (EFO_1000760), Nervous System Disease (EFO_0000618), Obesity (EFO_0001073), Fragile X Syndrome (MONDO_0010383), Atopic Eczema (EFO_0000274), Dementia (HP_0000726), Lymphoma (EFO_0000574), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Asthma (MONDO_0004979), Bronchiectasis (HP_0002110), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Chronic Bronchitis (EFO_0006505), Diabetic Nephropathy (EFO_0000401), Major Depressive Disorder (MONDO_0002009), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090), Dermatitis (MONDO_0002406)', 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.219 | Q22 | What is Epaned? | Epaned, also known generically as Enalapril Maleate, was approved by the FDA in 1985 to treat congestive heart failure, hypertension, and heart failure. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epaned%" OR LOWER(tradeNames_string) LIKE "%epaned%" OR LOWER(drugSynonyms_string) LIKE "%epaned%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6274', 'tradeNames_string': 'Ednyt, Enalapril maleate, Enapren, Epaned, Epaned kit, Innovace, Pralenal 10, Pralenal 2.5, Pralenal 20, Pralenal 5, Renitec, Vasotec, Xanef', 'drugName': 'Enalapril Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Angiotensin-converting enzyme inhibitor', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Preeclampsia (EFO_0000668), Intracerebral Hemorrhage (EFO_0005669), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Proteinuria (HP_0000093), Rheumatoid Arthritis (EFO_0000685)', 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.239 | Q22 | What is Minivelle? | Minivelle, also known generically as Estradiol, was approved by the FDA in 1975 to treat Premature ovarian insufficiency, Dyspareunia, and hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%minivelle%" OR LOWER(tradeNames_string) LIKE "%minivelle%" OR LOWER(drugSynonyms_string) LIKE "%minivelle%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6277', 'tradeNames_string': 'Adgyn estro, Alora, Aquagen, Bedol, Climara, Climara Pro, Dermestril 100, Dermestril 25, Dermestril 50, Dermestril septem 25, Dermestril septem 50, Dermestril septem 75, Divigel, E-Cypionate, Elestrim, Elestrin, Elleste solo, Elleste solo mx 40, Elleste solo mx 80, Esclim, Estrace, Estraderm, Estraderm mx 100, Estraderm mx 25, Estraderm mx 50, Estraderm mx 75, Estraderm tts 100, Estraderm tts 25, Estraderm tts 50, Estradiol, Estrasorb, Estring, Estrogel, Evamist, Evorel 100, Evorel 25, Evorel 50, Evorel 75, Fematrix 40, Fematrix 80, Fempatch, Femseven 100, Femseven 50, Femseven 75, Gvnodiol, Gynodiol, Gynogen, Imvexxy, Innofem, Menorest 37.5, Menorest 50, Menorest 75, Menoring 50, Menostar, Minivelle, Oestradiol, Progynova ts, Sandrena, Vagifem, Vagifem 18, Vagifem 8, Vivelle, Vivelle-dot, Zumenon', 'drugName': 'Estradiol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Estrogen receptor alpha agonist', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Migraine Disorder (MONDO_0005277), Dysmenorrhea (HP_0100607), Obesity (EFO_0001073), Dry Eye Syndrome (EFO_1000906), Atherosclerosis (EFO_0003914), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Hot Flashes (HP_0031217), Prostate Carcinoma (EFO_0001663), Breast Carcinoma (EFO_0000305), Myocardial Ischemia (EFO_1001375), Post-Traumatic Stress Disorder (EFO_0001358), Osteoporosis (EFO_0003882), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Breast Cancer (MONDO_0007254), Polycystic Ovary Syndrome (EFO_0000660), Osteopenia (HP_0000938), Postpartum Depression (EFO_0007453), Premature Ovarian Insufficiency (HP_0008209), Schizoaffective Disorder (EFO_0005411), Non-Alcoholic Steatohepatitis (EFO_1001249), Endometriosis (EFO_0001065), Amenorrhea (EFO_0010269), Sexual Dysfunction (EFO_0004714), Postmenopausal Atrophic Vaginitis (MONDO_0001410), Hypogonadism (MONDO_0002146), Turner Syndrome (MONDO_0019499), Menopause (EFO_0003922), Infertility (EFO_0000545), Urinary Tract Infection (EFO_0003103), Carcinoid Tumor (EFO_0004243), Hiv-1 Infection (EFO_0000180), Depressive Disorder (MONDO_0002050), Hiv Infection (EFO_0000764), Type 2 Diabetes Mellitus (MONDO_0005148), Atrophic Vaginitis (EFO_1001271), Blood Coagulation Disease (EFO_0009314), Atrophy (EFO_1000096), Bulimia Nervosa (EFO_0005204), Type 1 Diabetes Mellitus (MONDO_0005147), Dyspareunia (HP_0030016), Schizophrenia (MONDO_0005090), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.19 | Q22 | What is Alecensa? | Alecensa, also known generically as Alectinib, was approved by the FDA in 2015 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alecensa%" OR LOWER(tradeNames_string) LIKE "%alecensa%" OR LOWER(drugSynonyms_string) LIKE "%alecensa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4671', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'ALK tyrosine kinase receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Colorectal Neoplasm (EFO_0004142), Cholangiocarcinoma (EFO_0005221), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Bronchial Neoplasm (EFO_1000849), Ovarian Neoplasm (EFO_0003893), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4672', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Colorectal Neoplasm (EFO_0004142), Cholangiocarcinoma (EFO_0005221), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Bronchial Neoplasm (EFO_1000849), Ovarian Neoplasm (EFO_0003893), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4673', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'EML4-ALK', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Colorectal Neoplasm (EFO_0004142), Cholangiocarcinoma (EFO_0005221), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Bronchial Neoplasm (EFO_1000849), Ovarian Neoplasm (EFO_0003893), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1249', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'ALK tyrosine kinase receptor inhibitor', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1250', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1251', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'EML4-ALK', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.254 | Q22 | What is Fibricor? | Fibricor, also known generically as Fenofibric Acid, was approved by the FDA in 2008 to treat Hypercholesterolemia and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fibricor%" OR LOWER(tradeNames_string) LIKE "%fibricor%" OR LOWER(drugSynonyms_string) LIKE "%fibricor%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_347', 'tradeNames_string': 'Fenocor-67, Fenogal, Fibricor, Lipanthyl, Lipofen, Lofibra, Supralip, Trilipix', 'drugName': 'Fenofibric Acid', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor alpha agonist', 'linkedDiseasesDrug_string': 'Hypertriglyceridemia (EFO_0004211), Coronary Artery Disease (EFO_0001645), Medulloblastoma (EFO_0002939), Combined Hyperlipidemia (Orphanet_79211), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Cholestasis (MONDO_0001751), Disorder Of Lipid Metabolism (Orphanet_309005), Type 2 Diabetes Mellitus (MONDO_0005148), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'PPARA (ENSG00000186951)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.264 | Q22 | What is Children'S Allegra Hives? | Children'S Allegra Hives, also known generically as Fexofenadine Hydrochloride, was approved by the FDA in 1996 to treat seasonal allergic rhinitis, urticaria, allergic rhinitis, and allergic disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%children's allegra hives%" OR LOWER(tradeNames_string) LIKE "%children's allegra hives%" OR LOWER(drugSynonyms_string) LIKE "%children's allegra hives%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1045', 'tradeNames_string': "Allegra, Allegra allergy, Allegra hives, Children's allegra allergy, Children's allegra hives, Children's fexofenadine hydrochloride allergy, Children's fexofenadine hydrochloride hives, Fexofenadine hydrochloride, Fexofenadine hydrochloride allergy, Fexofenadine hydrochloride hives, Telfast 120, Telfast 180, Telfast 30", 'drugName': 'Fexofenadine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Allergic Rhinitis (EFO_0005854), Nephrolithiasis (EFO_0004253), Urticaria (EFO_0005531), Allergic Disease (MONDO_0005271)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.436 | Q22 | What is Singulair? | Singulair, also known generically as Montelukast Sodium, was approved by the FDA in 1998 to treat seasonal allergic rhinitis, allergic rhinitis, Rhinitis, Allergic, Perennial, and asthma. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%singulair%" OR LOWER(tradeNames_string) LIKE "%singulair%" OR LOWER(drugSynonyms_string) LIKE "%singulair%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2453', 'tradeNames_string': 'Montelukast sodium, Singulair', 'drugName': 'Montelukast Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Cysteinyl leukotriene receptor 1 antagonist', 'linkedDiseasesDrug_string': 'Rhinitis (EFO_0008521), Asthma (MONDO_0004979), Sepsis (HP_0100806), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Neonatal Sepsis (HP_0040187), Chronic Obstructive Pulmonary Disease (EFO_0000341), Eosinophilic Esophagitis (EFO_0004232), Allergic Rhinitis (EFO_0005854), Bronchiolitis Obliterans (EFO_0007183), Bronchiolitis (HP_0011950)', 'newLinkedTargets_string': 'CYSLTR1 (ENSG00000173198)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2189', 'tradeNames_string': 'Singulair', 'drugName': 'Montelukast', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Cysteinyl leukotriene receptor 1 antagonist', 'linkedDiseasesDrug_string': 'Status Asthmaticus (EFO_0008590), Multiple Myeloma (EFO_0001378), Alzheimer Disease (MONDO_0004975), Pain (EFO_0003843), Cough (HP_0012735), Covid-19 (MONDO_0100096), Allergic Rhinitis (EFO_0005854), Bronchiolitis Obliterans (EFO_0007183), Bronchiolitis (HP_0011950), Seasonal Allergic Rhinitis (EFO_0003956), Dengue Hemorrhagic Fever (EFO_0004227), Acute Lymphoblastic Leukemia (EFO_0000220), Non-Alcoholic Steatohepatitis (EFO_1001249), Acute Myeloid Leukemia (EFO_0000222), Immune System Disease (EFO_0000540), Asthma (MONDO_0004979), Respiratory System Disease (EFO_0000684), Premature Birth (EFO_0003917), Sepsis (HP_0100806), Rhinitis, Allergic, Perennial (EFO_1001417), Sickle Cell Anemia (MONDO_0011382), Neonatal Sepsis (HP_0040187), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Obstructive Sleep Apnea (EFO_0003918), Rheumatoid Arthritis (EFO_0000685), Wheezing (EFO_0009715), Sleep Apnea (EFO_0003877), Hiv Infection (EFO_0000764), Diabetic Nephropathy (EFO_0000401), Eosinophilic Esophagitis (EFO_0004232), Bronchopulmonary Dysplasia (MONDO_0019091), Severe Acute Respiratory Syndrome (EFO_0000694), Rhinitis (EFO_0008521)', 'newLinkedTargets_string': 'CYSLTR1 (ENSG00000173198)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.268 | Q22 | What is Oforta? | Oforta, also known generically as Fludarabine Phosphate, was approved by the FDA in 1991 to treat chronic lymphocytic leukemia, cancer, and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oforta%" OR LOWER(tradeNames_string) LIKE "%oforta%" OR LOWER(drugSynonyms_string) LIKE "%oforta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2916', 'tradeNames_string': 'Fludara, Fludarabine phosphate, Oforta', 'drugName': 'Fludarabine Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'DNA polymerase (alpha/delta/epsilon) inhibitor', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Skin Cancer (MONDO_0002898), Vasculitis (EFO_0006803), Refractory Anemia (EFO_0003802), Malignant Colon Neoplasm (MONDO_0021063), Lymphoid Neoplasm (EFO_0001642), Diamond-Blackfan Anemia (MONDO_0015253), Acute Myelomonocytic Leukemia (EFO_0000223), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Shwachman-Diamond Syndrome (MONDO_0009833), Aplastic Anemia (HP_0001915), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Immunodeficiency (HP_0002721), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Anemia (Phenotype) (EFO_0004272), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Severe Combined Immunodeficiency (MONDO_0015974), Wiskott-Aldrich Syndrome (MONDO_0010518), Acute Erythroleukemia (EFO_0000218), Hematopoietic And Lymphoid System Neoplasm (MONDO_0002334), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Osteosarcoma (EFO_0000637), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Ewing Sarcoma (EFO_0000174), Classic Hodgkin Lymphoma (MONDO_0009348), Epidermolysis Bullosa (EFO_1000690), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Lupus Nephritis (EFO_0005761), Osteopetrosis (MONDO_0017198), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Neuromyelitis Optica (EFO_0004256), Neuroepithelial Neoplasm (MONDO_0021193), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Squamous Cell Lung Carcinoma (EFO_0000708), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Beta-Thalassemia (Orphanet_848), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Myelofibrosis (MONDO_0044903), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Chronic Granulomatous Disease (MONDO_0018305), Embryonal Neoplasm (EFO_0005784), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Severe Aplastic Anemia (EFO_0006927), Thyroid Cancer (MONDO_0002108), Hodgkins Lymphoma (EFO_0000183), Metastatic Neoplasm (EFO_0009709), Prolymphocytic Leukemia (MONDO_0001023), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Hematologic Disease (EFO_0005803), Acute Monocytic Leukemia (EFO_0000221), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Bone Marrow Failure Syndrome (MONDO_0000159), Langerhans Cell Histiocytosis (EFO_1000318), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Primary Myelofibrosis (EFO_0002430), Pure Red Cell Aplasia (HP_0012410), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Hepatoblastoma (EFO_1000292), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Thalassemia (EFO_1001996), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), B-Cell Prolymphocytic Leukemia (EFO_1000102), Acute Megakaryoblastic Leukaemia (EFO_0003025), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), T-Cell Prolymphocytic Leukemia (EFO_1000560), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Graft Versus Host Disease (MONDO_0013730), Kidney Failure (EFO_1002048), Metastatic Melanoma (EFO_0002617), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Plasma Cell Leukemia (EFO_0006475), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Acute Erythroblastic Leukemia (EFO_1001257), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Chronic Myelomonocytic Leukemia (EFO_1001779), Cervical Carcinoma (EFO_0001061), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Refractory Anemia With Excess Blasts (EFO_0003811), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Lymphoid Leukemia (EFO_0004289), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Histiocytosis (HP_0100727), Esophageal Cancer (MONDO_0007576)", 'newLinkedTargets_string': 'RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848), POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1991, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2917', 'tradeNames_string': 'Fludara, Fludarabine phosphate, Oforta', 'drugName': 'Fludarabine Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Ribonucleoside-diphosphate reductase RR1 inhibitor', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Skin Cancer (MONDO_0002898), Vasculitis (EFO_0006803), Refractory Anemia (EFO_0003802), Malignant Colon Neoplasm (MONDO_0021063), Lymphoid Neoplasm (EFO_0001642), Diamond-Blackfan Anemia (MONDO_0015253), Acute Myelomonocytic Leukemia (EFO_0000223), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Shwachman-Diamond Syndrome (MONDO_0009833), Aplastic Anemia (HP_0001915), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Immunodeficiency (HP_0002721), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Anemia (Phenotype) (EFO_0004272), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Severe Combined Immunodeficiency (MONDO_0015974), Wiskott-Aldrich Syndrome (MONDO_0010518), Acute Erythroleukemia (EFO_0000218), Hematopoietic And Lymphoid System Neoplasm (MONDO_0002334), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Osteosarcoma (EFO_0000637), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Ewing Sarcoma (EFO_0000174), Classic Hodgkin Lymphoma (MONDO_0009348), Epidermolysis Bullosa (EFO_1000690), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Lupus Nephritis (EFO_0005761), Osteopetrosis (MONDO_0017198), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Neuromyelitis Optica (EFO_0004256), Neuroepithelial Neoplasm (MONDO_0021193), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Squamous Cell Lung Carcinoma (EFO_0000708), Myelodysplastic Syndrome (EFO_0000198), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Beta-Thalassemia (Orphanet_848), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Myelofibrosis (MONDO_0044903), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Chronic Granulomatous Disease (MONDO_0018305), Embryonal Neoplasm (EFO_0005784), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Severe Aplastic Anemia (EFO_0006927), Thyroid Cancer (MONDO_0002108), Hodgkins Lymphoma (EFO_0000183), Metastatic Neoplasm (EFO_0009709), Prolymphocytic Leukemia (MONDO_0001023), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Hematologic Disease (EFO_0005803), Acute Monocytic Leukemia (EFO_0000221), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Bone Marrow Failure Syndrome (MONDO_0000159), Langerhans Cell Histiocytosis (EFO_1000318), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Primary Myelofibrosis (EFO_0002430), Pure Red Cell Aplasia (HP_0012410), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Hepatoblastoma (EFO_1000292), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Thalassemia (EFO_1001996), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), B-Cell Prolymphocytic Leukemia (EFO_1000102), Acute Megakaryoblastic Leukaemia (EFO_0003025), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), T-Cell Prolymphocytic Leukemia (EFO_1000560), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Graft Versus Host Disease (MONDO_0013730), Kidney Failure (EFO_1002048), Metastatic Melanoma (EFO_0002617), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Plasma Cell Leukemia (EFO_0006475), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Acute Erythroblastic Leukemia (EFO_1001257), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Chronic Myelomonocytic Leukemia (EFO_1001779), Cervical Carcinoma (EFO_0001061), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Refractory Anemia With Excess Blasts (EFO_0003811), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Lymphoid Leukemia (EFO_0004289), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Histiocytosis (HP_0100727), Esophageal Cancer (MONDO_0007576)", 'newLinkedTargets_string': 'RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848), POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1991, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.62 | Q22 | What is Astepro? | Astepro, also known generically as Azelastine Hydrochloride, was approved by the FDA in 1996 to treat Nasal congestion, seasonal allergic rhinitis, allergic rhinitis, allergic conjunctivitis, vasomotor rhinitis, and Rhinitis, Allergic, Perennial. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%astepro%" OR LOWER(tradeNames_string) LIKE "%astepro%" OR LOWER(drugSynonyms_string) LIKE "%astepro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3567', 'tradeNames_string': "Astelin, Astepro, Astepro allergy, Azelastine hydrochloride, Children's astepro allergy, Optilast, Optivar, Rhinolast, Rhinolast allergy", 'drugName': 'Azelastine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Non-Allergic Rhinitis (EFO_0009364), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.217 | Q22 | What is Viberzi? | Viberzi, also known generically as Eluxadoline, was approved by the FDA in 2015 to treat irritable bowel syndrome. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%viberzi%" OR LOWER(tradeNames_string) LIKE "%viberzi%" OR LOWER(drugSynonyms_string) LIKE "%viberzi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6255', 'tradeNames_string': 'Truberzi, Viberzi', 'drugName': 'Eluxadoline', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.383 | Q22 | What is Loreev Xr? | Loreev Xr, also known generically as Lorazepam, was approved by the FDA in 1977 to treat unipolar depression, anxiety, anxiety disorder, status epilepticus, and depressive disorder. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%loreev xr%" OR LOWER(tradeNames_string) LIKE "%loreev xr%" OR LOWER(drugSynonyms_string) LIKE "%loreev xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3142', 'tradeNames_string': 'Abbloraz, Ativan, Loraz, Lorazepam, Lorazepam intensol, Lorazepam preservative free, Loreev xr, Temesta', 'drugName': 'Lorazepam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'GABA-A receptor; anion channel positive allosteric modulator', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Anxiety Disorder (EFO_0006788), Agitation (HP_0000713), Pain (EFO_0003843), Status Epilepticus (EFO_0008526), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Anxiety (EFO_0005230), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Withdrawal (EFO_0004777), Epilepsia Partialis Continua (EFO_1000924), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Obsessive-Compulsive Disorder (EFO_0004242), Delirium (EFO_0009267), Depressive Disorder (MONDO_0002050), Reflex Epilepsy (EFO_1001146), Alcohol Dependence (MONDO_0007079), Unipolar Depression (EFO_0003761), Voice Disorders (EFO_0009692), Peripheral Vertigo (MONDO_0004900), Major Depressive Disorder (MONDO_0002009), Epidermolysis Bullosa (EFO_1000690), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1977, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.30 | Q22 | What is Letairis? | Letairis, also known generically as Ambrisentan, was approved by the FDA in 2007 to treat hypertension, pulmonary arterial hypertension, pulmonary hypertension, and idiopathic and/or familial pulmonary arterial hypertension. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%letairis%" OR LOWER(tradeNames_string) LIKE "%letairis%" OR LOWER(drugSynonyms_string) LIKE "%letairis%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3910', 'tradeNames_string': 'Letairis, Volibris', 'drugName': 'Ambrisentan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Endothelin receptor, ET-A/ET-B antagonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Pulmonary Hypertension (MONDO_0005149), Hypertension (EFO_0000537), Idiopathic And/Or Familial Pulmonary Arterial Hypertension (MONDO_0008347), Hypoplastic Left Heart Syndrome (MONDO_0004933), Pulmonary Arterial Hypertension (EFO_0001361), Covid-19 (MONDO_0100096), Sickle Cell Anemia (MONDO_0011382), Vascular Disease (EFO_0004264), Idiopathic Pulmonary Fibrosis (EFO_0000768), Altitude Sickness (EFO_1000782)', 'newLinkedTargets_string': 'EDNRB (ENSG00000136160), EDNRA (ENSG00000151617)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.185 | Q22 | What is Pristiq? | Pristiq, also known generically as Desvenlafaxine Succinate, was approved by the FDA in 2008 to treat unipolar depression and major depressive disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pristiq%" OR LOWER(tradeNames_string) LIKE "%pristiq%" OR LOWER(drugSynonyms_string) LIKE "%pristiq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1437', 'tradeNames_string': 'Desvenlafaxine, Khedezla, Pristiq', 'drugName': 'Desvenlafaxine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Chronic Hepatitis C Virus Infection (EFO_0004220), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1438', 'tradeNames_string': 'Desvenlafaxine, Khedezla, Pristiq', 'drugName': 'Desvenlafaxine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Chronic Hepatitis C Virus Infection (EFO_0004220), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_735', 'tradeNames_string': 'Desvenlafaxine succinate, Pristiq', 'drugName': 'Desvenlafaxine Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_736', 'tradeNames_string': 'Desvenlafaxine succinate, Pristiq', 'drugName': 'Desvenlafaxine Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Diabetic Neuropathy (EFO_1000783), Menopause (EFO_0003922), Fibromyalgia (EFO_0005687), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Hot Flashes (HP_0031217)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.310 | Q22 | What is Makena (Autoinjector)? | Makena (Autoinjector), also known generically as Hydroxyprogesterone Caproate, was approved by the FDA in 1975 to treat premature birth. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%makena (autoinjector)%" OR LOWER(tradeNames_string) LIKE "%makena (autoinjector)%" OR LOWER(drugSynonyms_string) LIKE "%makena (autoinjector)%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4832', 'tradeNames_string': 'Delalutin, Hydroxyprogesterone caproate, Makena, Makena (autoinjector), Makena preservative free, Proluton depot', 'drugName': 'Hydroxyprogesterone Caproate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Progesterone receptor agonist', 'linkedDiseasesDrug_string': 'Pregnancy (EFO_0002950), Premature Birth (EFO_0003917)', 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.394 | Q22 | What is Lutathera? | Lutathera, also known generically as Lutetium Dotatate Lu-177, was approved by the FDA in 2018 to treat pancreatic neuroendocrine tumor and neuroendocrine neoplasm. It is a unknown therapy that acts as a(n) binding agent. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lutathera%" OR LOWER(tradeNames_string) LIKE "%lutathera%" OR LOWER(drugSynonyms_string) LIKE "%lutathera%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3035', 'tradeNames_string': 'Lutathera', 'drugName': 'Lutetium Dotatate Lu-177', 'drugMolecularType': 'Unknown', 'drugActionType': 'binding agent', 'drugMechanismOfAction': 'Somatostatin receptor binding agent', 'linkedDiseasesDrug_string': 'Neuroendocrine Neoplasm (EFO_1001901), Neuroblastoma (EFO_0000621), Pancreatic Neuroendocrine Tumor (EFO_1000045), Meningioma (MONDO_0016642), Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Pancreatic Endocrine Carcinoma (EFO_0007416), Breast Carcinoma (EFO_0000305), Neuroendocrine Carcinoma (MONDO_0002120), Grade Iii Meningioma (MONDO_0020634)', 'newLinkedTargets_string': 'SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR4 (ENSG00000132671), SSTR1 (ENSG00000139874), SSTR3 (ENSG00000278195)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.335 | Q22 | What is Lamictal Xr? | Lamictal Xr, also known generically as Lamotrigine, was approved by the FDA in 1994 to treat Seizure, Bilateral tonic-clonic seizure, bipolar disorder, epilepsy, unipolar depression, partial epilepsy, epilepsy with generalized tonic-clonic seizures, bipolar I disorder, depressive disorder, and Lennox-Gastaut syndrome. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lamictal xr%" OR LOWER(tradeNames_string) LIKE "%lamictal xr%" OR LOWER(drugSynonyms_string) LIKE "%lamictal xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5462', 'tradeNames_string': 'Lamictal, Lamictal cd, Lamictal odt, Lamictal xr, Lamotrigine', 'drugName': 'Lamotrigine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Peripheral Neuropathy (EFO_0003100), Bipolar I Disorder (EFO_0009963), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Obesity (EFO_0001073), Eating Disorder (EFO_0005203), Mood Disorder (EFO_0004247), Dementia (HP_0000726), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Partial Epilepsy (EFO_0004263), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Seizure (HP_0001250), Secondary Progressive Multiple Sclerosis (EFO_0008522), Drug Dependence (EFO_0003890), Mental Or Behavioural Disorder (EFO_0000677), Neurofibromatosis Type 1 (MONDO_0018975), Childhood Absence Epilepsy (MONDO_0010826), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Unipolar Depression (EFO_0003761), Hiv Infection (EFO_0000764), Cognitive Impairment (HP_0100543), Postherpetic Neuralgia (MONDO_0041052), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1994, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.443 | Q22 | What is Evzio? | Evzio, also known generically as Naloxone Hydrochloride, was approved by the FDA in 1971 to treat unipolar depression, pain, and septic shock. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%evzio%" OR LOWER(tradeNames_string) LIKE "%evzio%" OR LOWER(drugSynonyms_string) LIKE "%evzio%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3927', 'tradeNames_string': 'Evzio, Evzio (autoinjector), Kloxxado, Nalone, Naloxone, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Narcan, Narcan neonatal, Narconil, Prenoxad, Zimhi', 'drugName': 'Naloxone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Intestinal Obstruction (MONDO_0004565), Septic Shock (EFO_0006834), Pain (EFO_0003843), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.300 | Q22 | What is Bryhali? | Bryhali, also known generically as Halobetasol Propionate, was approved by the FDA in 1990 to treat psoriasis, skin disease, and psoriasis vulgaris. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bryhali%" OR LOWER(tradeNames_string) LIKE "%bryhali%" OR LOWER(drugSynonyms_string) LIKE "%bryhali%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1442', 'tradeNames_string': 'Bryhali, Halobetasol propionate, Lexette, Ultravate', 'drugName': 'Halobetasol Propionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Skin Disease (EFO_0000701), Atopic Eczema (EFO_0000274), Psoriasis Vulgaris (EFO_1001494)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1990, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.591 | Q22 | What is Nexavar? | Nexavar, also known generically as Sorafenib Tosylate, was approved by the FDA in 2005 to treat chromophobe renal cell carcinoma, clear cell renal carcinoma, papillary renal cell carcinoma, papillary thyroid carcinoma, renal cell carcinoma, thyroid carcinoma, and thyroid cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nexavar%" OR LOWER(tradeNames_string) LIKE "%nexavar%" OR LOWER(drugSynonyms_string) LIKE "%nexavar%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1543', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1544', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor FLT3 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1545', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase RAF inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1546', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1547', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1548', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1549', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_75', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_76', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor FLT3 inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_77', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase RAF inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_78', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_79', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_80', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_81', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.348 | Q22 | What is Eligard Kit? | Eligard Kit, also known generically as Leuprolide Acetate, was approved by the FDA in 1985 to treat metastatic prostate cancer, prostate adenocarcinoma, prostate carcinoma, Central precocious puberty, precocious puberty, prostate cancer, and central precocious puberty. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eligard kit%" OR LOWER(tradeNames_string) LIKE "%eligard kit%" OR LOWER(drugSynonyms_string) LIKE "%eligard kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4802', 'tradeNames_string': 'Carcinil, Eligard, Eligard kit, Fensolvi kit, Leuprolide acetate, Leuprorelin, Lupron, Lupron Depot Ped, Lupron depot, Lupron depot-ped, Lupron depot-ped kit, Lutrate depot kit, Viadur', 'drugName': 'Leuprolide Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Alzheimer Disease (MONDO_0004975), Male Infertility (EFO_0004248), Uterine Fibroid (EFO_0000731), Obesity (EFO_0001073), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Central Precocious Puberty (EFO_0009029), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Postpartum Depression (EFO_0007453), Hypertension (EFO_0000537), Endometriosis (EFO_0001065), Precocious Puberty (MONDO_0000088), Hodgkins Lymphoma (EFO_0000183), Cognitive Impairment (HP_0100543), Metastatic Prostate Cancer (EFO_0000196), Bulimia Nervosa (EFO_0005204)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.442 | Q22 | What is Narcan? | Narcan, also known generically as Naloxone, was approved by the FDA in 1971 to treat Constipation. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%narcan%" OR LOWER(tradeNames_string) LIKE "%narcan%" OR LOWER(drugSynonyms_string) LIKE "%narcan%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3927', 'tradeNames_string': 'Evzio, Evzio (autoinjector), Kloxxado, Nalone, Naloxone, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Narcan, Narcan neonatal, Narconil, Prenoxad, Zimhi', 'drugName': 'Naloxone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Intestinal Obstruction (MONDO_0004565), Septic Shock (EFO_0006834), Pain (EFO_0003843), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5202', 'tradeNames_string': 'Nalone, Narcan, Narcanti', 'drugName': 'Naloxone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Pain (EFO_0003843), Obesity (EFO_0001073), Irritable Bowel Syndrome (EFO_0000555), Hypogonadotropic Hypogonadism (MONDO_0018555), Eating Disorder (EFO_0005203), Hepatitis C Virus Infection (EFO_0003047), Morphine Dependence (EFO_0005612), Substance Withdrawal Syndrome (EFO_0005800), Septic Shock (EFO_0006834), Neuropathic Pain (EFO_0005762), Parkinson Disease (MONDO_0005180), Mycosis Fungoides (EFO_1001051), Epilepsy (EFO_0000474), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Restless Legs Syndrome (EFO_0004270), Drug Dependence (EFO_0003890), Diabetic Polyneuropathy (MONDO_0001583), Intestinal Obstruction (MONDO_0004565), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699), Unipolar Depression (EFO_0003761), Opioid Use Disorder (EFO_0010702), Osteoarthritis (MONDO_0005178), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Type 1 Diabetes Mellitus (MONDO_0005147)", 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.586 | Q22 | What is Januvia? | Januvia, also known generically as Sitagliptin Phosphate, was approved by the FDA in 2006 to treat myocardial infarction, stroke, type 2 diabetes mellitus, and hyperlipidemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%januvia%" OR LOWER(tradeNames_string) LIKE "%januvia%" OR LOWER(drugSynonyms_string) LIKE "%januvia%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2411', 'tradeNames_string': 'Janumet Xr, Januvia', 'drugName': 'Sitagliptin Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dipeptidyl peptidase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Renal Insufficiency (HP_0000083), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3574', 'tradeNames_string': 'Januvia', 'drugName': 'Sitagliptin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dipeptidyl peptidase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Psoriasis (EFO_0000676), Hyperlipidemia (MONDO_0021187), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Hepatitis C Virus Infection (EFO_0003047), Hepatocellular Carcinoma (EFO_0000182), Congestive Heart Failure (EFO_0000373), Acute Myocardial Infarction (EFO_0008583), Diabetic Foot (EFO_1001459), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Glucose Intolerance (HP_0001952), Acute Graft Vs. Host Disease (EFO_0004599), Renal Insufficiency (HP_0000083), Abnormal Glucose Tolerance (EFO_0002546), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Hiv-1 Infection (EFO_0000180), Chronic Kidney Disease (EFO_0003884), Prediabetes Syndrome (EFO_1001121), Cystic Fibrosis (MONDO_0009061), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'DPP4 (ENSG00000197635)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.332 | Q22 | What is Ninlaro? | Ninlaro, also known generically as Ixazomib Citrate, was approved by the FDA in 2015 to treat cancer, neoplasm, and multiple myeloma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ninlaro%" OR LOWER(tradeNames_string) LIKE "%ninlaro%" OR LOWER(drugSynonyms_string) LIKE "%ninlaro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3334', 'tradeNames_string': 'Ninlaro', 'drugName': 'Ixazomib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': '26S proteasome inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Al Amyloidosis (MONDO_0019438), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Plasmacytoma (EFO_0006738), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Anemia, Hemolytic, Autoimmune (EFO_1001264), Triple-Negative Breast Cancer (EFO_0005537), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Waldenstrom Macroglobulinemia (EFO_0009441), Chronic Kidney Disease (EFO_0003884), Follicular Lymphoma (MONDO_0018906), Hiv Infection (EFO_0000764), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Lupus Nephritis (EFO_0005761)', 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 0, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4407', 'tradeNames_string': 'Ninlaro', 'drugName': 'Ixazomib Citrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': '26S proteosome inhibitor', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Al Amyloidosis (MONDO_0019438), Neoplasm (EFO_0000616), Kaposi'S Sarcoma (EFO_0000558), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Plasmacytoma (EFO_0006738), Lymphoblastic Lymphoma (MONDO_0000873), Acute Myeloid Leukemia (EFO_0000222), Waldenstrom Macroglobulinemia (EFO_0009441), Glioblastoma Multiforme (EFO_0000519), Plasma Cell Leukemia (EFO_0006475)", 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.